JP2000026283A - Powder composition containing oily composition - Google Patents
Powder composition containing oily compositionInfo
- Publication number
- JP2000026283A JP2000026283A JP10195513A JP19551398A JP2000026283A JP 2000026283 A JP2000026283 A JP 2000026283A JP 10195513 A JP10195513 A JP 10195513A JP 19551398 A JP19551398 A JP 19551398A JP 2000026283 A JP2000026283 A JP 2000026283A
- Authority
- JP
- Japan
- Prior art keywords
- water
- weight
- oil
- solid phase
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 243
- 239000000843 powder Substances 0.000 title claims abstract description 106
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 122
- 239000007790 solid phase Substances 0.000 claims abstract description 107
- 239000012071 phase Substances 0.000 claims abstract description 89
- 239000013543 active substance Substances 0.000 claims abstract description 74
- 239000002245 particle Substances 0.000 claims abstract description 48
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 47
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 31
- 239000010419 fine particle Substances 0.000 claims abstract description 22
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 22
- 239000007864 aqueous solution Substances 0.000 claims abstract description 13
- 239000000839 emulsion Substances 0.000 claims description 71
- 229920000159 gelatin Polymers 0.000 claims description 42
- 108010010803 Gelatin Proteins 0.000 claims description 41
- 239000008273 gelatin Substances 0.000 claims description 41
- 235000019322 gelatine Nutrition 0.000 claims description 41
- 235000011852 gelatine desserts Nutrition 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 229920002472 Starch Polymers 0.000 claims description 30
- 235000019698 starch Nutrition 0.000 claims description 29
- 239000008107 starch Substances 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 21
- 238000001035 drying Methods 0.000 claims description 19
- 235000010489 acacia gum Nutrition 0.000 claims description 10
- 229920000084 Gum arabic Polymers 0.000 claims description 9
- 239000000205 acacia gum Substances 0.000 claims description 9
- 229920002488 Hemicellulose Polymers 0.000 claims description 8
- 239000003292 glue Substances 0.000 claims description 6
- 238000009629 microbiological culture Methods 0.000 claims description 6
- 229920001059 synthetic polymer Polymers 0.000 claims description 6
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000003860 storage Methods 0.000 abstract description 27
- 239000000243 solution Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 13
- 235000019640 taste Nutrition 0.000 abstract description 7
- 238000013268 sustained release Methods 0.000 abstract description 6
- 239000012730 sustained-release form Substances 0.000 abstract description 6
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 230000006866 deterioration Effects 0.000 abstract description 4
- 230000000873 masking effect Effects 0.000 abstract description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 abstract description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 abstract description 2
- 239000001593 sorbitan monooleate Substances 0.000 abstract description 2
- 229940035049 sorbitan monooleate Drugs 0.000 abstract description 2
- 230000001476 alcoholic effect Effects 0.000 abstract 2
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 125
- 235000019198 oils Nutrition 0.000 description 124
- 239000000284 extract Substances 0.000 description 66
- 239000008346 aqueous phase Substances 0.000 description 61
- -1 specifically Substances 0.000 description 47
- 235000019441 ethanol Nutrition 0.000 description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 26
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 22
- 240000008397 Ganoderma lucidum Species 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 238000002156 mixing Methods 0.000 description 22
- 239000007788 liquid Substances 0.000 description 21
- 239000002585 base Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 239000010408 film Substances 0.000 description 15
- 235000011187 glycerol Nutrition 0.000 description 15
- 235000013305 food Nutrition 0.000 description 14
- 235000010323 ascorbic acid Nutrition 0.000 description 13
- 239000011668 ascorbic acid Substances 0.000 description 13
- 229960005070 ascorbic acid Drugs 0.000 description 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 12
- 235000010445 lecithin Nutrition 0.000 description 12
- 239000000787 lecithin Substances 0.000 description 12
- 229940067606 lecithin Drugs 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 235000012424 soybean oil Nutrition 0.000 description 11
- 239000003549 soybean oil Substances 0.000 description 11
- 239000000835 fiber Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 10
- 240000008042 Zea mays Species 0.000 description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 9
- 239000000654 additive Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 244000215068 Acacia senegal Species 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 8
- 235000005822 corn Nutrition 0.000 description 8
- 230000001804 emulsifying effect Effects 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229960005069 calcium Drugs 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 235000020710 ginseng extract Nutrition 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- 241000222336 Ganoderma Species 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000004373 Pullulan Substances 0.000 description 6
- 229920001218 Pullulan Polymers 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 6
- 235000013923 monosodium glutamate Nutrition 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000003531 protein hydrolysate Substances 0.000 description 6
- 235000019423 pullulan Nutrition 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 229940073490 sodium glutamate Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229960002920 sorbitol Drugs 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 230000008719 thickening Effects 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 244000124853 Perilla frutescens Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241001122767 Theaceae Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229940066675 ricinoleate Drugs 0.000 description 4
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 238000005809 transesterification reaction Methods 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 241000237502 Ostreidae Species 0.000 description 3
- 235000019484 Rapeseed oil Nutrition 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229940023476 agar Drugs 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000021323 fish oil Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 235000020636 oyster Nutrition 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- PAZZVPKITDJCPV-UHFFFAOYSA-N 10-hydroxyoctadecanoic acid Chemical compound CCCCCCCCC(O)CCCCCCCCC(O)=O PAZZVPKITDJCPV-UHFFFAOYSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241001632410 Eleutherococcus senticosus Species 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- WTAYIFXKJBMZLY-XZABIIKCSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O WTAYIFXKJBMZLY-XZABIIKCSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 241000241413 Propolis Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 241000270666 Testudines Species 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229940105990 diglycerin Drugs 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- VTTZNHFOGZURNY-UHFFFAOYSA-L disodium;2-oct-1-enylbutanedioate Chemical compound [Na+].[Na+].CCCCCCC=CC(C([O-])=O)CC([O-])=O VTTZNHFOGZURNY-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000013804 distarch phosphate Nutrition 0.000 description 2
- 239000001245 distarch phosphate Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229940080237 sodium caseinate Drugs 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 235000019583 umami taste Nutrition 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000008307 w/o/w-emulsion Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FHYUZZZBYFIZFH-NBTZWHCOSA-N (9Z,12Z)-octadeca-9,12-dienoic acid propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O FHYUZZZBYFIZFH-NBTZWHCOSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- VNJHUUNVDMYCRH-UHFFFAOYSA-N 1,1-diphenyl-3-piperidin-1-ylpropan-1-ol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 VNJHUUNVDMYCRH-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZONJATNKKGGVSU-UHFFFAOYSA-N 14-methylpentadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCC(O)=O ZONJATNKKGGVSU-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- PUHLHLQBIFRKRD-CSKARUKUSA-N 5-methyl-2-[(E)-2-phenylethenyl]-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1\C=C\C1=CC=CC=C1 PUHLHLQBIFRKRD-CSKARUKUSA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- CFLUVFXTJIEQTE-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COC(=O)CCCCCCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COC(=O)CCCCCCCCCCCCCCCCC CFLUVFXTJIEQTE-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102100037888 DnaJ homolog subfamily B member 12 Human genes 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 241000987738 Gloydius blomhoffii Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000208251 Gymnema Species 0.000 description 1
- 241000208253 Gymnema sylvestre Species 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 235000015030 Hedychium spicatum Nutrition 0.000 description 1
- 240000003237 Hedychium spicatum Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000805849 Homo sapiens DnaJ homolog subfamily B member 12 Proteins 0.000 description 1
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 description 1
- 241000384508 Hoplostethus atlanticus Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920003012 Hydroxypropyl distarch phosphate Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 241000270711 Malaclemys terrapin Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- NYIIDPYDLJYGAY-GRVYQHKQSA-N OCC(O)CO.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O Chemical compound OCC(O)CO.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O NYIIDPYDLJYGAY-GRVYQHKQSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000543810 Sasa veitchii Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 102100031083 Uteroglobin Human genes 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000077233 Vaccinium uliginosum Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- 244000131415 Zanthoxylum piperitum Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- PZQBWGFCGIRLBB-NJYHNNHUSA-N [(2r)-2-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1O PZQBWGFCGIRLBB-NJYHNNHUSA-N 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 229940069780 barley extract Drugs 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 229940098391 carbetapentane citrate Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940072104 cholesteryl hydroxystearate Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- DCJGJEZFCWRDSY-UHFFFAOYSA-L disodium 1,3-dimethylpurin-7-ide-2,6-dione acetate Chemical compound [Na+].[Na+].CC([O-])=O.Cn1c2nc[n-]c2c(=O)n(C)c1=O DCJGJEZFCWRDSY-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 239000004499 emulsifiable powder Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229940072117 fennel extract Drugs 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 239000010647 garlic oil Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 229950011212 glymidine sodium Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000013825 hydroxy propyl distarch phosphate Nutrition 0.000 description 1
- 239000001310 hydroxy propyl distarch phosphate Substances 0.000 description 1
- DVROLKBAWTYHHD-UHFFFAOYSA-N hydroxy propyl distarch phosphate Chemical compound OC1C(O)C(OC)OC(CO)C1OC(O)CCOC1C(OC2C(C(O)C(OC3C(C(OP(O)(=O)OC4C(C(O)C(OC)OC4CO)O)C(C)OC3CO)O)OC2COC2C(C(O)C(OC)C(CO)O2)O)O)OC(CO)C(OC)C1O DVROLKBAWTYHHD-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000019690 meat sausages Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960001397 methdilazine hydrochloride Drugs 0.000 description 1
- IEISBKIVLDXSMZ-UHFFFAOYSA-N methdilazine hydrochloride Chemical compound Cl.C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 IEISBKIVLDXSMZ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000013807 monostarch phosphate Nutrition 0.000 description 1
- 239000001248 monostarch phosphate Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- KMNJKLJBUHNCQM-UHFFFAOYSA-N octadecanoic acid propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O KMNJKLJBUHNCQM-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 235000020733 paullinia cupana extract Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- QFRKWSPTCBGLSU-UHFFFAOYSA-M potassium 4-hydroxy-3-methoxybenzene-1-sulfonate Chemical compound [K+].COC1=CC(S([O-])(=O)=O)=CC=C1O QFRKWSPTCBGLSU-UHFFFAOYSA-M 0.000 description 1
- 229940069505 potassium guaiacolsulfonate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229960003195 pridinol Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000020752 sage extract Nutrition 0.000 description 1
- 229940112950 sage extract Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 229940119463 sunflower seed extract Drugs 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000896 tipepidine Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-VBJOUPRGSA-N triricinolein Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC)COC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-VBJOUPRGSA-N 0.000 description 1
- 229960002655 tubocurarine chloride Drugs 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Fodder In General (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、食品、飼料、化粧
品、医薬品、農薬、機械その他各種工業分野において利
用できる、水溶性有効物質及び/又は水分散性有効物質
(以下水性有効物質という)、及び水溶性フィルム形成
剤を含有し、場合によっては多価アルコール等を含有す
る微粒子が、油相中に分散した油性組成物を含有する粉
末組成物に関するものである。The present invention relates to a water-soluble active substance and / or a water-dispersible active substance (hereinafter referred to as an aqueous active substance) which can be used in food, feed, cosmetics, pharmaceuticals, agricultural chemicals, machinery and various other industrial fields. The present invention relates to a powder composition containing an oily composition in which fine particles containing a water-soluble film-forming agent and, in some cases, a polyhydric alcohol or the like are dispersed in an oil phase.
【0002】[0002]
【従来の技術】水性有効物質の味をマスキングしたり、
徐放性機能を持たせたり、体内での吸収性を上げたり、
長期保存性を高めたりする目的で、水性有効物質のカプ
セル化が行われている。水性有効成分のカプセル化法と
して、コアソルベーション法、液中乾燥法、多重乳化法
等がある。コアソルベーション法は、硬化剤としてホル
ムアルデヒドやグルタルアルデヒド等の毒性のある溶剤
を用いている。また、この調製方法は、実製造化が難し
い。液中乾燥法を用いた水溶性薬剤のカプセルとして特
公平7−20859号公報等が提案されている。しか
し、一般に液中乾燥法は、壁膜ポリマー溶解物質とし
て、ベンゼン、塩化メチレン、クロロホルム、四塩化炭
素、酢酸エチル等の毒性を有する溶剤を用いている。ま
た、液中乾燥法によるマイクロカプセル調製では、水性
有効物質を含有するW/O型乳化物を水相に添加混合し
てW/O/W型乳化物としている。このW/O/W型乳
化物は、内水相中に水を含有するため、内水相中の水性
有効物質が外水相中へ溶出することは避けられなかっ
た。よって液中乾燥法により得られるマイクロカプセル
では、水溶性物質のカプセル化は満足できるものではな
かった。また、特公平4−24974号公報等では、W
/O/W型乳化物を乾燥してW/O/W型乳化性粉末を
調製しているが、乾燥後もW/O乳化物が保持されてい
るため、内水相には水を含有する。そのため、長期保存
時に内水相が腐敗したり、内水相中の水溶性物質が劣化
したり、粉末基材に内水相の水が溶出して粉末の流動性
が低下する恐れがある。また、内水相に含有する水溶性
物質の外部への溶出調整は難しい。このように、これま
での製法により得られる水性有効物質含有カプセルは、
使用する材料、製造方法、コスト、保存安定性等におい
てさまざまな規制や問題があるため、十分満足できるも
のではなかった。特に、使用する原材料が制限される食
品、医薬品、化粧品分野においては、その実用化が困難
であった。BACKGROUND OF THE INVENTION Masking the taste of aqueous active substances,
To have a sustained release function, to increase the absorption in the body,
Aqueous active substances have been encapsulated for the purpose of enhancing long-term storage. Examples of the method for encapsulating the aqueous active ingredient include a core solvation method, a submerged drying method, and a multiple emulsification method. The core solvation method uses a toxic solvent such as formaldehyde or glutaraldehyde as a curing agent. In addition, this preparation method is difficult to commercialize. Japanese Patent Publication No. 7-20859 has been proposed as a capsule of a water-soluble drug using a submerged drying method. However, in general, the in-liquid drying method uses a toxic solvent such as benzene, methylene chloride, chloroform, carbon tetrachloride, and ethyl acetate as the wall film polymer dissolving substance. In the preparation of microcapsules by a submerged drying method, a W / O emulsion containing an aqueous active substance is added to and mixed with an aqueous phase to form a W / O / W emulsion. Since the W / O / W emulsion contains water in the inner aqueous phase, it is inevitable that the aqueous active substance in the inner aqueous phase elutes into the outer aqueous phase. Therefore, in the microcapsules obtained by the submerged drying method, encapsulation of the water-soluble substance was not satisfactory. In Japanese Patent Publication No. 4-24974, etc., W
The W / O / W type emulsified powder is prepared by drying the / O / W type emulsified product, but since the W / O emulsified product is retained even after drying, the inner aqueous phase contains water. I do. Therefore, the internal aqueous phase may rot during long-term storage, the water-soluble substance in the internal aqueous phase may be degraded, or the water of the internal aqueous phase may be eluted into the powder base material and the fluidity of the powder may be reduced. Further, it is difficult to adjust the elution of the water-soluble substance contained in the internal aqueous phase to the outside. Thus, the aqueous active substance-containing capsule obtained by the conventional manufacturing method,
There were various regulations and problems in the materials used, the manufacturing method, the cost, the storage stability, and the like, so that they were not sufficiently satisfactory. In particular, in the fields of foods, medicines, and cosmetics in which raw materials to be used are restricted, it has been difficult to put them to practical use.
【0003】[0003]
【発明が解決しようとする課題】従って、本発明の目的
は、保存時に水性有効物の劣化や分解を抑え、水性有効
物質の味の低減効果や徐放性効果、マスキング効果、体
内吸収率向上効果を有した粉末組成物を提供することに
ある。SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to suppress the deterioration and decomposition of an aqueous active substance during storage, to reduce the taste of the aqueous active substance, to provide a sustained release effect, a masking effect, and to improve the absorption rate in the body. An object of the present invention is to provide a powder composition having an effect.
【0004】[0004]
【課題を解決するための手段】本発明者らは上記実情に
鑑み、鋭意研究を行った結果、水性有効物質を特定の微
粒子状態で油相中に分散させ、且つ固体相中の水分含有
量又はアルコール水溶液含有量を特定の量にした油性組
成物を含有した粉末組成物が上記目的を達成し得ること
を知見した。本発明において、固体相とは、水性有効物
質及び水溶性フィルム形成剤を含有し、水分含有量又は
アルコール水溶液含有量が30重量%以下で、場合によ
っては多価アルコール等を含有する相のことである。本
発明は、上記知見に基づいてなされたもので、水性有効
物質、水溶性フィルム形成剤を含有し、水分含有量又は
アルコール水溶液含有量が30重量%以下で、場合によ
っては多価アルコール等を含有する固体相と、油性成分
及び親油性乳化剤を含有してなる油相とからなる油性組
成物を含有することを特徴とする粉末組成物を提供する
ものである。本発明の粉末組成物は、粉末基材に油性組
成物粒子が吸着または内包しており、その粒子中には固
体相微粒子が分散しているものである。本発明の粉末組
成物は、W/O/W型乳化性粉末のように水性有効物質
が水溶液状態ではなく、固体状態として油性成分に被覆
されているため、水性有効物質自体の劣化、分解、腐敗
等を防止することができる。また、W/O/W型乳化性
粉末と違って、油相から粉末基材への水の溶出が起こら
ないため、長期保存を行っても粉末流動性は低下しな
い。粉末化した油性組成物の固体相中の水溶性フィルム
含量調整により、粉末中の油性組成物が水に接触した場
合の水性有効物質の水への溶出量調整が可能となる。さ
らに、水性有効物質が、固体状態で水溶性フィルムおよ
び油性成分に被覆されているため、腸管で吸収される水
性有効物質を含有する本発明品を摂取した場合、摂取後
に水性有効物質に結合する吸収阻害物質や水性有効物質
を消化する消化管酵素からの攻撃を受けにくい。したが
って、水性有効物質が活性を保持したまま腸管吸収部位
まで輸送されるため吸収率が向上する。Means for Solving the Problems In view of the above-mentioned circumstances, the present inventors have made intensive studies and as a result, have found that an aqueous active substance is dispersed in a specific fine particle state in an oil phase, and the water content in a solid phase is reduced. Alternatively, it has been found that a powder composition containing an oily composition having a specific amount of an aqueous alcohol solution can achieve the above object. In the present invention, the solid phase refers to a phase containing an aqueous active substance and a water-soluble film-forming agent, having a water content or an aqueous alcohol content of 30% by weight or less, and optionally containing a polyhydric alcohol or the like. It is. The present invention has been made based on the above findings, and contains an aqueous active substance, a water-soluble film-forming agent, a water content or an aqueous alcohol solution content of 30% by weight or less, and in some cases, a polyhydric alcohol or the like. It is intended to provide a powder composition comprising an oily composition comprising a solid phase to be contained and an oily phase containing an oily component and a lipophilic emulsifier. In the powder composition of the present invention, the oil-based composition particles are adsorbed or included in the powder base material, and the solid phase fine particles are dispersed in the particles. Since the powdery composition of the present invention has a water-based active substance that is not in an aqueous solution state but is coated with an oily component as a solid state like a W / O / W-type emulsifiable powder, deterioration, decomposition, Corrosion and the like can be prevented. Further, unlike the W / O / W type emulsifying powder, the elution of water from the oil phase to the powder base does not occur, so that the powder fluidity does not decrease even after long-term storage. By adjusting the content of the water-soluble film in the solid phase of the powdered oily composition, it becomes possible to adjust the amount of the aqueous active substance eluted into water when the oily composition in the powder comes into contact with water. Furthermore, since the aqueous active substance is coated with the water-soluble film and the oily component in a solid state, when the product of the present invention containing the aqueous active substance absorbed in the intestinal tract is ingested, it binds to the aqueous active substance after ingestion. Less susceptible to gastrointestinal enzymes that digest absorption inhibitors and aqueous active substances. Therefore, the absorption rate is improved because the aqueous active substance is transported to the intestinal absorption site while maintaining the activity.
【0005】[0005]
【発明の実施の形態】以下、本発明に用いられる油性組
成物について詳述する。本発明に用いられる油性組成物
は、水性有効物質及び水溶性フィルム形成剤を含有し、
場合によっては多価アルコール等を含有した固体相と、
油性成分及びHLBが10以下の乳化剤を含有してなる
油相とからなる。BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the oily composition used in the present invention will be described in detail. The oily composition used in the present invention contains an aqueous active substance and a water-soluble film forming agent,
In some cases, a solid phase containing a polyhydric alcohol or the like,
An oil component and an oil phase containing an emulsifier having an HLB of 10 or less.
【0006】まず、本発明に用いられる油性組成物の固
体相について説明する。本発明において用いられる水性
有効物質は、水に溶解するもの及び/又は水に分散する
ものであれば何でも良いが、水又はアルコール水溶液に
溶解するものが望ましい。また、水性有効物質の製造方
法に制限はない。例えば、酸味料、色素、着色料、香
料、抗酸化剤、酵素、菌類、調味料、無機塩類、澱粉、
澱粉加水分解物、ペプチド、生理活性を有するポリペプ
チド、アミノ酸、食物繊維、セルロース、栄養強化剤、
生薬エキス、糖尿病治療剤、解熱剤、消炎剤、鎮痛剤、
鎮静剤、抗アレルギー剤、抗生物質、抗潰瘍剤、抗腫瘍
剤、抗凝血剤、止血剤、強心剤、筋弛緩剤、麻酔剤、不
整脈治療剤、血管拡張剤等の薬剤、ワクチン、動植物抽
出物質が挙げられ、具体的には、クエン酸及びその塩
類、リン酸及びその塩類、メタリン酸及びその塩類、ク
チナシ青色色素、カラメル、カカオ色素、ブドウ果皮色
素、ストロベリー色素、シソ色素、フォスフォリパー
ゼ、アミラーゼ、デヒドロゲナーゼ、タカヂアスターゼ
N1、乳酸菌、酪酸菌、ビフィズス菌、核酸、酵母、タ
ウリン、食塩、醤油、炭酸ナトリウム、クエン酸ナトリ
ウム、コーン澱粉、デキストリン、乳ペプチド、コーン
ペプチド、インスリン、ソマトスタチン、甲状腺刺激ホ
ルモン、副甲状腺ホルモン、成長ホルモン、黄体形成ホ
ルモン放出ホルモン、L−トリプトファン、塩化リジ
ン、グルタミン酸ナトリウム、アスパラギン酸ナトリウ
ム、ポリデキストロース、微結晶セルロース、アスコル
ビン酸及びその塩類、ニコチン酸アミド、ニコチン酸、
リン酸L−アスコルビン酸マグネシウム、ビタミンB
類、ナイアシン、パントテン酸カルシウム、葉酸、ビオ
チン、塩化カルシウム等のカルシウム塩類、乳性ミネラ
ル、乳酸カルシウム、カゼイン・カルシウム・ペプチド
(CCP)、カゼインホスホペプチド(CPP)、カル
シウムサイトレマート(CCM)、牛骨粉、貝殻粉、へ
ム鉄、亜鉛、アルブチン、コウジ酸、ニフェジピン、ユ
ビデカレノン、ニカルジピン、メソトレキセート、ソマ
トスタチン、塩酸フェンフォルミン、グリピザイド、塩
酸ブフォルミン、グリミジンナトリウム、サリチル酸ナ
トリウム、フルフェナム酸ナトリウム、スルピリン、プ
ロクロルペラジン、塩酸クロルプロマジン、塩酸ジフェ
ンヒドラミン、塩酸メトジラジン、マレイン酸クロルフ
ェニラミン、アミカシン、トブラマイシン、リビドマイ
シン、ゲンタマイシン、カネンドマイシン、塩酸テトラ
サイクリン、ジベカシン、アンピシリン、メトクロプロ
ミド、マイトマイシンC、塩酸ブレオマイシン、アクチ
ノマイシンD、メソトレキセート、塩酸ダウノルビシ
ン、硫酸ビンクリスチン、硫酸ビスブラスチン、アドリ
アマイシン、レンチナン、グリチルリチン、ヘパリンナ
トリウム、トロンビン、トロンボプラスチン、トランス
パイオキソカンファー、アミノフィリン、テオフィロー
ル、メタンスルホン酸プリジノール、塩化ツボクラリ
ン、塩酸ブフェトロール、塩酸ジルチアゼム、塩酸オキ
シフェドン、グリチルリチン酸ジカリウム、マレイン酸
クロフェニラミン、リン酸コデイン、アスピリン、アセ
トアミノフェノン、d−マレイン酸クロルフェニラミ
ン、ヒベンズ酸チペピジン、ビスベンチアミン、メタケ
イ酸アルミン酸マグネシウム、クエン酸カルベタペンタ
ン、グアヤコールスルホン酸カリウム、インフルエンザ
ワクチン、ギムネマ、ギムネマシルベスタ抽出物、ハト
ムギエキス、蜂蜜、ローヤルゼリー、プロポリス、羅漢
果抽出物、ハーブエキス、ぶどう抽出物、ブルーベリー
抽出物、ブルーベリ葉抽出物、ローズマリー抽出物、茶
抽出物、カテキン、杜仲エキス、ロートエキス、ポーレ
ン、ナリンジン、香辛料抽出物、こけもも抽出物、カフ
ェイン、オウバク末、ヨード、コバルト、セレニウム、
オリゴ糖、キシロオリゴ糖、ニンニク抽出物、シイタケ
エキス、わさび、たで、マツバエキス、バジル、コカ、
さんしょう、しそ、しそ抽出物、辛子、米糠酵素分解
物、クロレラ、タウリン、スピルリナ、エゾウコギ、キ
チン、キトサン、ルチン、紅花抽出物、生コーヒー豆抽
出物、ヒマワリ種子抽出物、アロエ、イソアルファー苦
味酸、ゲンチアナ抽出物、霊芝、霊芝抽出物、冬虫夏
草、マムシエキス、マローエキス、スッポンエキス、カ
キエキス、ヨモギ抽出物、クコシ、クコ、クマザサエキ
ス、高麗人参エキス、田七人参エキス、イチョウ葉エキ
ス、人参の葉エキス、オクタコサノール、シャクヤク、
エンゴサク、リョウキョウ、シュクシャ、ボレイ、エン
ゴサク、ケイヒエキス、ダイダイエキス、カキ葉エキ
ス、クズ花エキス、ウイキョウエキス、ショウガエキ
ス、エゾウコギエキス、サンザシエキス、ガラナエキ
ス、オウセイエキス、カンゾウエキス、イソロイシン、
トレオニン、フェニルアラニン、ナリンジン、ナイアシ
ンアミド、リジン、スレオニン、アルギニン、ガラナ、
カキニクエキス、ギムネマシルベスタエキス、トナカイ
ホーンエキス、ステビア、深海ザメエキス、オットセイ
エキス、しらこ蛋白、プラセンタエキス等が挙げられ
る。上記水性有効物質は、単独で用いても良く、又は2
種類以上を組み合わせて用いても良い。また、上記水性
有効物質の含有量は、油性組成物の固体相の全重量に対
して5〜95重量%であり、好ましくは5〜80重量%
であり、更に好ましくは10〜70重量%である。First, the solid phase of the oily composition used in the present invention will be described. The aqueous active substance used in the present invention may be any substance that dissolves in water and / or disperses in water, but is preferably one that dissolves in water or an aqueous alcohol solution. In addition, there is no limitation on the method for producing the aqueous active substance. For example, acidulants, pigments, colorants, flavors, antioxidants, enzymes, fungi, seasonings, inorganic salts, starch,
Starch hydrolyzate, peptide, biologically active polypeptide, amino acid, dietary fiber, cellulose, nutritional enhancer,
Herbal extract, antidiabetic, antipyretic, anti-inflammatory, analgesic,
Sedatives, antiallergic agents, antibiotics, antiulcer agents, antitumor agents, anticoagulants, hemostatic agents, cardiotonic agents, muscle relaxants, anesthetics, arrhythmic drugs, vasodilators, etc., vaccines, animal and plant extracts Substances, specifically, citric acid and its salts, phosphoric acid and its salts, metaphosphoric acid and its salts, gardenia blue pigment, caramel, cacao pigment, grape skin pigment, strawberry pigment, perilla pigment, phospholipase , Amylase, dehydrogenase, takapiastase N1, lactic acid bacteria, butyric acid bacteria, bifidobacteria, nucleic acids, yeast, taurine, salt, soy sauce, sodium carbonate, sodium citrate, corn starch, dextrin, milk peptide, corn peptide, insulin, somatostatin, thyroid stimulation Hormones, parathyroid hormone, growth hormone, luteinizing hormone-releasing hormone, - tryptophan, lysine chloride, sodium glutamate, sodium aspartate, polydextrose, microcrystalline cellulose, ascorbic acid and salts thereof, nicotinamide, nicotinic acid,
Phosphate L-magnesium ascorbate, vitamin B
, Niacin, calcium pantothenate, folic acid, biotin, calcium salts such as calcium chloride, milk mineral, calcium lactate, casein calcium peptide (CCP), casein phosphopeptide (CPP), calcium cytoremate (CCM), Beef bone meal, shell powder, heme iron, zinc, arbutin, kojic acid, nifedipine, ubidecarenone, nicardipine, methotrexate, somatostatin, fenformin hydrochloride, glipizide, buformin hydrochloride, glymidine sodium, sodium salicylate, sodium flufenamic acid, sulpirin, Prochlorperazine, chlorpromazine hydrochloride, diphenhydramine hydrochloride, methdilazine hydrochloride, chlorpheniramine maleate, amikacin, tobramycin, ribidomycin, gentamicin , Canendomycin, tetracycline hydrochloride, dibekacin, ampicillin, metoclopromide, mitomycin C, bleomycin hydrochloride, actinomycin D, methotrexate, daunorubicin hydrochloride, vincristine sulfate, bisblastine sulfate, adriamycin, lentinan, glycyrrhizin, heparin sodium, thrombin, thromboplastin Pioxocamphor, aminophylline, theophyllol, pridinol methanesulfonate, tubocurarine chloride, bufetrol hydrochloride, diltiazem hydrochloride, oxyphedone hydrochloride, dipotassium glycyrrhizinate, clophenylamine maleate, codeine phosphate, aspirin, acetaminophenone, d-maleic acid Chlorpheniramine, tipepidine hibenzate, visbentia , Magnesium aluminate metasilicate, carbetapentane citrate, potassium guaiacolsulfonate, influenza vaccine, gymnema, gymnemasylvesta extract, barley extract, honey, royal jelly, propolis, arhat extract, herbal extract, grape extract, blueberry Extract, Blueberry leaf extract, Rosemary extract, Tea extract, Catechin, Tochu extract, Roth extract, Pollen, Naringin, Spice extract, Kokemo extract, Caffeine, Oubak powder, Iodine, Cobalt, Selenium ,
Oligosaccharides, xylooligosaccharides, garlic extract, shiitake mushroom extract, wasabi, ash, Matsuba extract, basil, coca,
Sansho, shiso, shiso extract, hot pepper, rice bran enzyme digest, chlorella, taurine, spirulina, eleuthero, chitin, chitosan, rutin, safflower extract, green coffee bean extract, sunflower seed extract, aloe, isoalpha bitterness Acid, gentian extract, reishi, reishi extract, cordyceps, mamushi extract, mallow extract, turtle extract, oyster extract, mugwort extract, kukushi, wolfberry, kumazasa extract, ginseng extract, ginseng extract, ginkgo leaf extract, Ginseng leaf extract, octacosanol, peonies,
Engosaku, Ryokyo, Shukusha, Borei, Engosaku, Keihi Extract, Daidai Extract, Oyster Leaf Extract, Kuzu Flower Extract, Fennel Extract, Ginger Extract, Eleuthero, Hawthorn Extract, Guarana Extract, Oyster Extract, Licorice Extract, Isoleucine,
Threonine, phenylalanine, naringin, niacinamide, lysine, threonine, arginine, guarana,
Examples include oyster extract, gymnema sylvestre extract, reindeer horn extract, stevia, deep-sea shark extract, fur seal extract, shirako protein, and placenta extract. The aqueous active substance may be used alone or 2
A combination of more than two types may be used. The content of the aqueous active substance is 5 to 95% by weight, preferably 5 to 80% by weight based on the total weight of the solid phase of the oily composition.
And more preferably 10 to 70% by weight.
【0007】本発明に用いられる水溶性フィルム形成剤
とは、その水溶液を乾燥したときにフィルムを形成する
もので、例えば、ゼラチン、にかわ、アラビアガム、澱
粉微生物培養物、ヘミセルロース、水溶性被膜形成合成
高分子等が挙げられる。上記ゼラチンとは、動物の骨や
皮に多く含まれるコラーゲンを分解・抽出・精製・乾燥
等の処理をしたポリペプチドのことをいい、食品、飼
料、化粧品、医薬品、工業等の分野で利用されているも
のを特に制限なく用いることができる。さらに、漂白精
製等を行った精製ゼラチンも用いることができる。上記
にかわとしては、ゼラチンの不純物の多いものであっ
て、食品、飼料、化粧品、医薬品、工業等の分野で一般
に利用されているものである。上記アラビアガムとは、
食品、飼料、化粧品、医薬品、工業等の分野で一般に利
用されているものである。上記澱粉微生物培養物は、澱
粉を微生物培養した後、抽出・精製・乾燥等の処理をし
た中性多糖類で、食品、飼料、化粧品、医薬品、工業等
の分野で一般に利用されているものである。澱粉微生物
培養物として、例えば、プルランが挙げられる。上記ヘ
ミセルロースとは、針葉樹、広葉樹、イネ科植物、種
子、種子皮等から抽出・精製した水溶性多糖質であり、
また、これらを、酸、アルカリ等による化学的処理や、
熱、圧力等による物理的処理、酵素等による生物的処理
によって加水分解したものである。上記ヘミセルロース
は、食品、飼料、化粧品、医薬品、工業等の分野で一般
に利用されているものである。ヘミセルロースとして、
例えば、カラマツ属樹木中から抽出・精製したアラビノ
ガラクタン、トウモロコシの種皮から抽出・精製したコ
ーンファイバー(例えば、日本食品化工(株)製、セル
エース#40)、大豆から抽出・精製したファイバー
(不二製油(株)製、ソヤファイブ−S)、小麦粉のキ
シラン等が挙げられる。本発明において用いられる水溶
性被膜形成合成高分子とは、例えば、カルボキシルメチ
ルセルロース、メチルセルロース、セルロースアセテー
トフタレート、ポリアクリル酸ナトリウム、ポリビニル
アルコール、ポリビニルピロリドン、ポリビニルメチル
エーテル、カルボキシビニルポリマー、ハイドロキシエ
チルセルロース、ハイドロキシプロピルメチルセルロー
ス、カーボポール、ポリ(メチルビニルエーテル/無水
マレイン酸)で、化粧品、医薬品、工業等の分野で一般
に利用されているものである。上記水溶性フィルム形成
剤は、単独で用いてもよく、又は2種以上を組み合わせ
て用いてもよい。上記水溶性フィルム形成剤の固体相中
の含有量は、1〜95重量%、好ましくは5〜80重量
%、さらに好ましくは10〜70重量%である。水溶性
フィルムが水性有効成分を覆って固化することで、固体
相同士の合一が防止されるため、油相中の固体相の分散
安定性が向上する。水溶性フィルム形成剤が配合されて
いない場合、その分散油の保存安定性は低下する。さら
に、水溶性フィルム形成剤添加量を調整することによ
り、油性組成物が水に接触した時の水性有効物質の水中
への溶出量調整が可能となる。つまり、水性有効物質1
00重量部に対して水溶性フィルム形成剤量が50重量
部より少ない場合、好ましくは25重量部より少ない場
合、油性組成物から外部の水中へ水性有効物質が徐々に
溶出するが、水性有効物質100重量部に対して水溶性
フィルム形成剤量が50重量部より多い場合、好ましく
は80重量部、より好ましくは100重量部より多い場
合、油性組成物から外部の水中への水性有効物質の溶出
をかなり抑えることができる。The water-soluble film-forming agent used in the present invention forms a film when the aqueous solution is dried. Examples thereof include gelatin, glue, gum arabic, starch microbial culture, hemicellulose, and water-soluble film-forming agent. And synthetic polymers. The above-mentioned gelatin refers to a polypeptide obtained by treating collagen such as degraded, extracted, purified, and dried in a large amount in bones and skins of animals, and is used in fields such as food, feed, cosmetics, pharmaceuticals, and industry. Can be used without particular limitation. Further, purified gelatin which has been subjected to bleaching purification can also be used. The glue described above is a gelatin containing a large amount of impurities and generally used in the fields of food, feed, cosmetics, pharmaceuticals, industry and the like. The above gum arabic is
It is commonly used in the fields of food, feed, cosmetics, pharmaceuticals, industry and the like. The above-mentioned starch microbial culture is a neutral polysaccharide obtained by subjecting starch to microbial cultivation and then subjecting it to extraction, purification, drying, and the like, and is generally used in the fields of food, feed, cosmetics, pharmaceuticals, industry, and the like. is there. Examples of the starch microorganism culture include pullulan. The hemicellulose is a water-soluble polysaccharide extracted and purified from conifers, hardwoods, grasses, seeds, seed coats, and the like,
Further, these are subjected to a chemical treatment with an acid, an alkali or the like,
It has been hydrolyzed by physical treatment with heat, pressure, or the like, or biological treatment with an enzyme or the like. The above-mentioned hemicellulose is generally used in the fields of food, feed, cosmetics, pharmaceuticals, industry and the like. As hemicellulose,
For example, arabinogalactan extracted and purified from larch trees, corn fiber extracted and purified from maize seed coat (for example, Cell Ace # 40 manufactured by Nippon Shokuhin Kako Co., Ltd.), and fiber extracted and purified from soybean (non- Soya Five-S, manufactured by Nii Oil Co., Ltd., and xylan of flour. The water-soluble film-forming synthetic polymer used in the present invention includes, for example, carboxymethylcellulose, methylcellulose, cellulose acetate phthalate, sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinylmethylether, carboxyvinyl polymer, hydroxyethylcellulose, hydroxypropyl Methyl cellulose, carbopol, and poly (methyl vinyl ether / maleic anhydride), which are generally used in the fields of cosmetics, pharmaceuticals, industry, and the like. The water-soluble film forming agents may be used alone or in combination of two or more. The content of the water-soluble film-forming agent in the solid phase is 1 to 95% by weight, preferably 5 to 80% by weight, more preferably 10 to 70% by weight. Since the solidification of the water-soluble film covering the aqueous active ingredient prevents the solid phases from coalescing, the dispersion stability of the solid phase in the oil phase is improved. When the water-soluble film forming agent is not blended, the storage stability of the dispersed oil is reduced. Further, by adjusting the amount of the water-soluble film-forming agent added, it becomes possible to adjust the amount of the aqueous active substance eluted into water when the oily composition comes into contact with water. That is, the aqueous active substance 1
When the amount of the water-soluble film-forming agent is less than 50 parts by weight, preferably less than 25 parts by weight, the aqueous active substance gradually elutes from the oily composition to external water. When the amount of the water-soluble film-forming agent is more than 50 parts by weight, preferably 80 parts by weight, more preferably more than 100 parts by weight, the elution of the aqueous active substance from the oily composition to the external water per 100 parts by weight Can be considerably reduced.
【0008】本発明に用いられる多価アルコールは種々
のものを使用できるが、分子内に2個以上、より好まし
くは2〜12個、さらに好ましくは2〜6個の水酸基を
有する水溶性のものがよい。例えばグルコース、マルト
ース、マルチトール、ソルビタン、ソルビトール、ショ
糖、乳糖、フルクトース、キシリトール、イノシトー
ル、エリスリトール、ペンタエリスリトール、プロピレ
ングリコール、1,3−ブチレングリコール、エチレン
グリコール、グリセリン、ジグリセリン、トリグリセリ
ン、ポリグリセリン(平均重合度:4〜10)、還元澱
粉糖化物、ブドウ糖果糖液糖、果糖ブドウ糖液糖等を挙
げることができる。これらは単独で又は2種以上組み合
わせて用いることができる。多価アルコールを固体相に
添加することにより、油性組成物の40℃での長期保存
性と耐冷凍性がより向上する。上記多価アルコールの固
体相中の含有量は、1〜90重量%、好ましくは5〜8
0重量%、さらに好ましくは5〜70重量%である。こ
こで、固体相中には、水溶性フィルム形成剤及び多価ア
ルコールの双方を含有させてもよいし、水溶性フィルム
形成剤のみ、又は多価アルコールのみを含有させてもよ
い。Various polyhydric alcohols can be used in the present invention, and water-soluble alcohols having 2 or more, more preferably 2 to 12, and more preferably 2 to 6 hydroxyl groups in the molecule can be used. Is good. For example, glucose, maltose, maltitol, sorbitan, sorbitol, sucrose, lactose, fructose, xylitol, inositol, erythritol, pentaerythritol, propylene glycol, 1,3-butylene glycol, ethylene glycol, glycerin, diglycerin, triglycerin, poly Glycerin (average degree of polymerization: 4 to 10), saccharified reduced starch, fructose fructose liquid sugar, fructose dextrose liquid sugar, and the like can be given. These can be used alone or in combination of two or more. By adding the polyhydric alcohol to the solid phase, the long-term storage at 40 ° C. and the freezing resistance of the oily composition are further improved. The content of the polyhydric alcohol in the solid phase is 1 to 90% by weight, preferably 5 to 8%.
0% by weight, more preferably 5 to 70% by weight. Here, in the solid phase, both a water-soluble film forming agent and a polyhydric alcohol may be contained, or only the water-soluble film forming agent or only a polyhydric alcohol may be contained.
【0009】本発明に用いられる油性組成物の固体相に
は、必要に応じて、増粘安定剤を添加することができ
る。用いられる増粘剤としては、キサンタンガム、グア
ーガム、ローカストビーンガム、カラギーナン、寒天、
ペクチン、アルギン酸ナトリウム、ジェランガム等が挙
げられる。増粘剤を添加する場合、その含有量は、油性
組成物の固体相中に好ましくは0.01〜5重量%であ
る。[0009] If necessary, a thickening stabilizer can be added to the solid phase of the oily composition used in the present invention. Xanthan gum, guar gum, locust bean gum, carrageenan, agar,
Pectin, sodium alginate, gellan gum and the like. When a thickener is added, its content is preferably 0.01 to 5% by weight in the solid phase of the oily composition.
【0010】本発明に用いる水としては、特に制限はな
く、精製水、蒸留水及び水道水等を用いることができ
る。また、上記水にアルコールを加えることもできる。
該アルコールとしては、例えば、エタノール及びメタノ
ール等の一価アルコールが挙げられる。この場合のアル
コールの使用量は、水100重量部に対し、1〜300
重量部程度が好ましい。[0010] The water used in the present invention is not particularly limited, and purified water, distilled water, tap water and the like can be used. In addition, alcohol can be added to the water.
Examples of the alcohol include monohydric alcohols such as ethanol and methanol. In this case, the amount of the alcohol used is 1 to 300 parts per 100 parts by weight of water.
It is preferably about parts by weight.
【0011】本発明に用いられる油性組成物の固体相に
は、必要に応じて、HLBが10以上の乳化剤を添加す
ることができる。用いられる乳化剤のHLBは20以下
であることが好ましい。HLBが10以上の乳化剤とし
ては、ショ糖脂肪酸エステル、ポリグリセリン脂肪酸エ
ステル、抽出レシチン、酵素分解レシチン、水添レシチ
ン、サポニン、糖脂質、蛋白質、蛋白加水分解物(ゼラ
チン、にかわを除く)、シリコーン系乳化剤、アルキレ
ンオキサイド付加乳化剤等が挙げられる。HLBが10
以上の乳化剤を添加する場合、その含有量は、油性組成
物の全重量に対して、好ましくは0.01〜5重量%で
ある。[0011] If necessary, an emulsifier having an HLB of 10 or more can be added to the solid phase of the oily composition used in the present invention. The emulsifier used preferably has an HLB of 20 or less. Emulsifiers having an HLB of 10 or more include sucrose fatty acid ester, polyglycerin fatty acid ester, extracted lecithin, enzymatically decomposed lecithin, hydrogenated lecithin, saponin, glycolipid, protein, protein hydrolyzate (excluding gelatin and glue), silicone System emulsifier, alkylene oxide addition emulsifier, and the like. HLB is 10
When the above emulsifier is added, its content is preferably 0.01 to 5% by weight based on the total weight of the oil composition.
【0012】更に、本発明に用いられる油性組成物の固
体相には、公知の防腐剤、着色料、香料、又はpH調製
剤等の添加剤を添加することができる。該添加剤を添加
する場合、その含有量は、油性組成物の固体相の全重量
に対して、好ましくは0.01〜5重量%である。Further, known additives such as preservatives, coloring agents, perfumes, and pH adjusters can be added to the solid phase of the oily composition used in the present invention. When the additive is added, its content is preferably 0.01 to 5% by weight based on the total weight of the solid phase of the oily composition.
【0013】本発明に用いられる油性組成物の固体相
は、その水分含有量又はアルコール水溶液含有量が30
重量%以下であり、好ましくは20重量%以下であり、
さらに好ましくは10重量%以下であり、最も好ましく
は5重量%以下である。固体相中の水分含有量が又はア
ルコール水溶液含有量が30重量%より多い場合、油性
組成物の保存安定性が低下し、水性有効物質が劣化した
りする。この油性組成物を用いて粉末組成物を調製した
場合、油相粒子中に水性有効物質を安定分散させるのは
難しい。本発明に用いられる油性組成物の固体相の水分
含有量又はアルコール水溶液含有量を30重量%以下に
する方法に特に制限はないが、例えば、減圧乾燥、加熱
乾燥、薄膜蒸留乾燥及び凍結乾燥等の方法により実施す
ることができる。The solid phase of the oily composition used in the present invention has a water content or an aqueous alcohol solution content of 30.
% By weight or less, preferably 20% by weight or less,
It is more preferably at most 10% by weight, most preferably at most 5% by weight. When the water content or the aqueous alcohol solution content in the solid phase is more than 30% by weight, the storage stability of the oily composition is reduced, and the aqueous active substance is deteriorated. When a powder composition is prepared using this oily composition, it is difficult to stably disperse the aqueous active substance in the oil phase particles. The method for reducing the water content or the aqueous alcohol solution content of the solid phase of the oily composition used in the present invention to 30% by weight or less is not particularly limited. Examples thereof include vacuum drying, heat drying, thin film distillation drying, and freeze drying. It can be carried out by the method described above.
【0014】本発明に用いられる油性組成物の固体相
は、平均粒子径5μm以下の微粒子状態で、後述する油
相中に分散している。固体相の平均粒子径は好ましくは
3μm以下であり、さらに好ましくは0.05〜2μm
である。固体相の平均粒子径が、5μmより大きい場
合、油性組成物の保存安定性が著しく低下する。この油
性組成物を用いて粉末組成物を調製した場合、油相粒子
中に固体相微粒子を安定分散させることは難しい。油相
中に分散する固体相を平均粒子径5μm以下の微粒子状
態にする方法に特に制限はないが、例えば、油相と水相
とをゆっくり混合しながらホモミキサーを用いて約30
分間混合、乳化させるか、又は、高圧ホモジナイザ−、
マイクロフルイダイザー等の乳化機を用いて最終的にW
/O型乳化物を得、これを乾燥処理することにより得ら
れる。ここで、「最終的にW/O型乳化物を得」とは、
乳化初期段階でW/O型やO/W型であっても、O/W
型及びW/O型の混合物であっても、最終的にW/O型
になれば良いという意味である。なお、本発明におい
て、固体相の平均粒子径とは、レーザー回折式粒度分布
測定装置(LA−500型、(株)堀場製作所製)を用
いて測定した値である。The solid phase of the oily composition used in the present invention is dispersed in the oil phase described below in the form of fine particles having an average particle diameter of 5 μm or less. The average particle size of the solid phase is preferably 3 μm or less, more preferably 0.05 to 2 μm.
It is. When the average particle size of the solid phase is larger than 5 μm, the storage stability of the oily composition is significantly reduced. When a powder composition is prepared using this oily composition, it is difficult to stably disperse the solid phase fine particles in the oil phase particles. There is no particular limitation on the method of converting the solid phase dispersed in the oil phase into fine particles having an average particle diameter of 5 μm or less. For example, while slowly mixing the oil phase and the aqueous phase, about 30
Minutes, emulsified or high pressure homogenizer,
Finally, using an emulsifier such as a microfluidizer,
/ O type emulsion is obtained and dried. Here, “to finally obtain a W / O emulsion”
Even if it is W / O type or O / W type at the initial stage of emulsification,
Even if it is a mixture of a mold and a W / O type, it means that it is sufficient that the mixture finally becomes a W / O type. In the present invention, the average particle diameter of the solid phase is a value measured by using a laser diffraction type particle size distribution analyzer (LA-500, manufactured by Horiba, Ltd.).
【0015】次に、本発明に用いられる油性組成物の油
相について説明する。該油相は、乳化剤及び油性成分を
含有してなるものである。上記乳化剤としては、食品、
飼料、化粧品、医薬品及び工業等の分野で利用される公
知の乳化剤を下記に述べる以外は特に制限なく用いるこ
とができる。本発明において用いられる乳化剤として
は、HLBが10以下の乳化剤を用いるのが好ましい。
またHLBが1以上の乳化剤を用いるのが好ましい。H
LBが10より大きい乳化剤のみを用いた場合、W/O
型乳化物の調製ができないため油性組成物が得られな
い。Next, the oil phase of the oil composition used in the present invention will be described. The oil phase contains an emulsifier and an oil component. Foods, as the emulsifier,
Known emulsifiers used in the fields of feed, cosmetics, pharmaceuticals, industry and the like can be used without particular limitation except as described below. As the emulsifier used in the present invention, it is preferable to use an emulsifier having an HLB of 10 or less.
It is preferable to use an emulsifier having an HLB of 1 or more. H
When only an emulsifier having an LB greater than 10 is used, W / O
An oily composition cannot be obtained because a type emulsion cannot be prepared.
【0016】HLBが10以下の乳化剤としては、例え
ば、ソルビタン脂肪酸エステル、グリセリン脂肪酸エス
テル、有機酸モノグリセライド、プロピレングリコール
脂肪酸エステル、ジグリセライド、ショ糖脂肪酸エステ
ル、ポリグリセリン脂肪酸エステル、水添レシチン、レ
シチン、シリコーン系乳化剤、アルキレンオキサイド付
加界面活性剤等が挙げられ、具体的にはソルビタンモノ
オレート、ソルビタンジステアレート、ポリオキシエチ
レン(6モル)ソルビタンモノステアレート、グリセリ
ンモノステアレート、グリセリンモノリノレート、クエ
ン酸とグリセリンモノオレートのエステル化物、プロピ
レングリコールモノステアレート、グリセリンジオレー
ト、グリセリンジリノレート、なたね油とグリセリンの
エステル交換により得られたジグリセライド、サフラワ
ーとグリセリンのエステル交換により得られたジグリセ
ライド、ジグリセリンジステアレート、ジグリセリント
リステアレート、ヘキサグリセリントリオレート、ヘキ
サグリセリンペンタステアレート、テトラグリセリン縮
合リシノレート、ポリグリセリン縮合リシノレイン酸エ
ステル、ショ糖トリないしペンタステアリン酸エステ
ル、ポリオキシエチレン(5モル)セチルエーテル、ポ
リオキシエチレン(3モル)ノニルフェニルエーテル、
ポリオキシエチレン(6モル)ステアリルエーテル、ポ
リオキシエチレン(5モル)硬化ヒマシ油、ポリオキシ
エチレン(15モル)硬化ヒマシ油、ポリオキシエチレ
ン(20モル)ソルビトールテトラオレート、レシチン
(日清製油(株)製、レシチンDX、ベイシスLP−2
0)、水添レシチン(日清製油(株)製、ベイシスLP
−20H)、ジメチルシロキサン・メチル(ポリオキシ
エチレン5モル付加)シロキサン共重合体、ジメチルシ
ロキサン・メチル(ポリオキシエチレン5モル付加)シ
ロキサン・メチル(ポリオキシプロピレン5モル付加)
シロキサン共重合体等が挙げられる。本発明において
は、上記乳化剤を単独で用いてもよく、又は2種以上を
組み合わせてもよい。Examples of the emulsifier having an HLB of 10 or less include sorbitan fatty acid ester, glycerin fatty acid ester, organic acid monoglyceride, propylene glycol fatty acid ester, diglyceride, sucrose fatty acid ester, polyglycerin fatty acid ester, hydrogenated lecithin, lecithin, silicone And a surfactant such as a sorbitan monooleate, a sorbitan distearate, a polyoxyethylene (6 mol) sorbitan monostearate, a glycerin monostearate, a glycerin monolinolate, and a citric acid. Esterification of acid and glycerin monooleate, propylene glycol monostearate, glycerindiolate, glycerin dilinoleate, and transesterification of rapeseed oil and glycerin. Diglyceride obtained, diglyceride obtained by transesterification of safflower and glycerin, diglycerin distearate, diglycerin tristearate, hexaglycerin triolate, hexaglycerin pentastearate, tetraglycerin condensed ricinoleate, polyglycerin condensed ricinolein Acid ester, sucrose tri-pentastearate, polyoxyethylene (5 mol) cetyl ether, polyoxyethylene (3 mol) nonylphenyl ether,
Polyoxyethylene (6 mol) stearyl ether, polyoxyethylene (5 mol) hydrogenated castor oil, polyoxyethylene (15 mol) hydrogenated castor oil, polyoxyethylene (20 mol) sorbitol tetraolate, lecithin (Nisshin Oil Co., Ltd. ), Lecithin DX, Basis LP-2
0), hydrogenated lecithin (Basis LP, manufactured by Nisshin Oil Co., Ltd.)
-20H), dimethylsiloxane / methyl (addition of 5 moles of polyoxyethylene) siloxane copolymer, dimethylsiloxane / methyl (addition of 5 moles of polyoxyethylene), siloxane / methyl (addition of 5 moles of polyoxypropylene)
Examples include siloxane copolymers. In the present invention, the above-mentioned emulsifiers may be used alone or in combination of two or more.
【0017】また、本発明においては、HLB10以下
の乳化剤にHLBが10以上の乳化剤を併用してもよ
い。そのような乳化剤としては、例えば、ショ糖脂肪酸
エステル、ポリグリセリン脂肪酸エステル、抽出レシチ
ン、酵素分解レシチン、水添レシチン、サポニン、糖脂
質、蛋白質、蛋白加水分解物(ゼラチン、にかわを除
く)、シリコーン系界面活性剤、アルキレンオキサイド
付加界面活性剤等がある。具体的には、ショ糖ステアリ
ン酸モノエステル、ヘキサグリセリンオレイン酸モノエ
ステル、デカグリセリンステアリン酸モノエステル、抽
出レシチン(日清製油(株)製、ベイシスLS−6
0)、酵素分解レシチン(日清製油(株)製、ベイシス
LG−10K、ベイシスLP−20E)、水添レシチン
(日清製油(株)製、ベイシスLS−60H)、キラヤ
サポニン、大豆蛋白加水分解物、カゼインナトリウム、
小麦グルテン加水分解物、ジメチルシロキサン・メチル
(ポリオキシエチレン60モル付加)シロキサン共重合
体、ポリオキシエチレン(25モル)硬化ヒマシ油、ポ
リオキシエチレン(80モル)硬化ヒマシ油等が挙げら
れる。本発明ではとりわけポリグリセリン縮合リシノル
酸エステル単独、又はこれとポリグリセリン脂肪酸エス
テルあるいはグリセリンモノ脂肪酸エステルやレシチン
との併用が望ましい。本発明においては、上記乳化剤の
単独又は2種以上を組み合わせたものを親油性乳化剤と
併用することができる。In the present invention, an emulsifier having an HLB of 10 or more may be used in combination with an emulsifier having an HLB of 10 or less. Examples of such emulsifiers include sucrose fatty acid esters, polyglycerin fatty acid esters, extracted lecithin, enzymatically decomposed lecithin, hydrogenated lecithin, saponins, glycolipids, proteins, protein hydrolysates (excluding gelatin and glue), silicones Surfactants and alkylene oxide-added surfactants. Specifically, sucrose stearic acid monoester, hexaglycerin oleic acid monoester, decaglycerin stearic acid monoester, extracted lecithin (manufactured by Nisshin Oil Co., Ltd., Basis LS-6)
0), enzymatically-decomposed lecithin (Basis LG-10K, Basis LP-20E, manufactured by Nisshin Oil Co., Ltd.), hydrogenated lecithin (Basis LS-60H, manufactured by Nisshin Oil Co., Ltd.), Kiyala saponin, soybean protein hydrolysate Degradation products, sodium caseinate,
Wheat gluten hydrolyzate, dimethylsiloxane / methyl (polyoxyethylene 60 mol addition) siloxane copolymer, polyoxyethylene (25 mol) hydrogenated castor oil, polyoxyethylene (80 mol) hydrogenated castor oil, and the like. In the present invention, it is particularly desirable to use polyglycerin condensed ricinoleate alone or in combination with polyglycerin fatty acid ester, glycerin monofatty acid ester or lecithin. In the present invention, one or a combination of two or more of the above emulsifiers can be used in combination with a lipophilic emulsifier.
【0018】本発明で用いられる油性成分としては、食
品、飼料、化粧品、医薬品、工業等の分野で利用される
公知の油性成分を特に制限なく用いることができる。該
油性成分としては、液体状態のものを用いるが、常温で
液体状態のものでもよく、また、加温により溶解するも
のであれば、特に制限なく用いることができる。該油性
成分としては、例えば、炭化水素類、エステル類、動植
物性油脂類、ワックス類、ハゼ脂、高級脂肪酸類、高級
アルコール類、シリコーン系物質、ステロール類、樹脂
類等、これらを酵素的処理(加水分解、エステル交換
等)や化学的処理(エステル交換、水素添加等)したも
の等が該当する。製造上及び取り扱い面から油相は、常
温で液状か流動性を有する状態のものを用いるのが好ま
しい。これらの例として大豆油、なたね油、コーン油、
ごま油、綿実油、サフラワー油、ひまわり油、落花生
油、米胚芽油、小麦胚芽油、玄米胚芽油、ハトムギ油、
マカダミアンナッツ油、ガーリックオイル、ツバキ油、
パーム油、オリーブ油、ホホバ油、マカデミアンナッツ
油、アボガド油、ヒマシ油、アマニ油、シソ油、ユーカ
リ油、月見草油、タートル油、ミンク油、豚脂、牛脂、
馬油、蛇油、魚油、卵油、卵黄油、流動パラフィン、イ
ソパラフィン、ワセリン、スクワラン、スクワレン、テ
レピン油、ミリスチン酸イソプロピルエステル、ミリス
チン酸イソパルミチルエステル、ミリスチン酸2−オク
チルドデシルエステル、2−エチルヘキサン酸セチルエ
ステル、トリ−2−エチルヘキサン酸グリセリルエステ
ル、トリ−カプリル酸グリセリルエステル、カプリル酸
及びカプリン酸の混合脂肪酸のトリグリセリド、ジ−2
−エチルヘキサン酸ネオペンチルグリコールエステル、
リンゴ酸ジイソステアリルエステル、イソノナン酸イソ
ノニルエステル(3,5,5−トリメチルヘキシル−
3’,5’,5’−トリメチルヘキサノエート)、12
−ヒドロキシステアリン酸コレステリルエステル、エメ
リー社製イソステアリン酸及び/又は高級脂肪酸とジペ
ンタエリスリトールとのモノエステルないしヘキサエス
テル、パラメトキシケイ皮酸及び2−エチルヘキサン酸
のグリセリンエステル、パラメトキシケイ皮酸イソオク
チルエステル等をあげることができる。As the oil component used in the present invention, known oil components used in the fields of food, feed, cosmetics, pharmaceuticals, industry and the like can be used without particular limitation. The oily component is in a liquid state, but may be in a liquid state at normal temperature, or may be used without particular limitation as long as it can be dissolved by heating. Examples of the oily component include enzymatic treatment of hydrocarbons, esters, animal and vegetable fats and oils, waxes, goby fat, higher fatty acids, higher alcohols, silicone-based substances, sterols, and resins. (Hydrolysis, transesterification, etc.) and chemically treated (transesterification, hydrogenation, etc.), etc. From the viewpoint of production and handling, it is preferable to use an oil phase which is liquid or fluid at normal temperature. Examples of these are soybean oil, rapeseed oil, corn oil,
Sesame oil, cottonseed oil, safflower oil, sunflower oil, peanut oil, rice germ oil, wheat germ oil, brown rice germ oil, oat oil,
Macadamian nut oil, garlic oil, camellia oil,
Palm oil, olive oil, jojoba oil, macadamian nut oil, avocado oil, castor oil, linseed oil, perilla oil, eucalyptus oil, evening primrose oil, turtle oil, mink oil, lard, tallow,
Horse oil, snake oil, fish oil, egg oil, egg yolk oil, liquid paraffin, isoparaffin, petrolatum, squalane, squalene, turpentine oil, isopropyl myristate, isopalmityl myristate, 2-octyldodecyl myristate, 2- Cetyl ethylhexanoate, glyceryl tri-2-ethylhexanoate, glyceryl tri-caprylate, triglyceride of mixed fatty acid of caprylic acid and capric acid, di-2
-Neopentyl glycol ethylhexanoate,
Diisostearyl malate, isononyl isononanoate (3,5,5-trimethylhexyl-
3 ', 5', 5'-trimethylhexanoate), 12
Cholesteryl hydroxystearate, monoester or hexaester of isostearic acid and / or higher fatty acid and dipentaerythritol manufactured by Emery Co., glycerol ester of paramethoxycinnamic acid and 2-ethylhexanoic acid, iso-paramethoxycinnamate Octyl ester and the like can be mentioned.
【0019】また大豆硬化油、なたね硬化油、パーム硬
化油、魚硬化油、トリステアリン酸グリセリルエステ
ル、ロジン、コレステロール、フィトステロール(カン
ペステロール、スチグマステロール、シトステロール
等)、オレンジラフィー油、ラノリン、ミリスチン酸、
パルミチン酸、イソパルミチン酸、ステアリン酸、エメ
リー社製イソステアリン酸、オレイン酸、リノール酸、
リノレン酸、リシノール酸、12−ヒドロキシステアリ
ン酸、10−ヒドロキシステアリン酸、ベヘン酸、エル
シン酸、アラキドン酸、エイコサペンタエン酸、ドコサ
ヘキサエン酸、ミリスチルアルコール、セチルアルコー
ル、ステアリルアルコール、イソステアリルアルコー
ル、ベヘニルアルコール、ラノリンアルコール、パラフ
ィンワックス、マイクロクリスタリンワックス、セレシ
ンワックス、ミツロウ、ワセリン、ハードファット、カ
ルナウバワックス、キャンデリラワックス、ライスワッ
クス、米ぬかワックス、木ろうセラック、ジメチルポリ
シロキサン、メチルフェニルポリシロキサン、動植物由
来の精油成分等も対象とすることができる。これら油性
成分は、単独で用いてもよく、又は2種以上を組み合わ
せて用いてもよい。本発明に用いられる油性組成物の油
相中の上記乳化剤の含有量は、好ましくは0.5〜50
重量%であり、更に好ましくは1〜30重量%である。Hardened soybean oil, hardened rapeseed oil, hardened palm oil, hardened fish oil, glyceryl tristearate, rosin, cholesterol, phytosterols (campesterol, stigmasterol, sitosterol, etc.), orange roughy oil, lanolin, Myristic acid,
Palmitic acid, isopalmitic acid, stearic acid, isomeric isoleic acid, linoleic acid,
Linolenic acid, ricinoleic acid, 12-hydroxystearic acid, 10-hydroxystearic acid, behenic acid, erucic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, myristyl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, lanolin Alcohol, paraffin wax, microcrystalline wax, ceresin wax, beeswax, petrolatum, hard fat, carnauba wax, candelilla wax, rice wax, rice bran wax, wood wax shellac, dimethyl polysiloxane, methylphenyl polysiloxane, essential oils derived from animals and plants Components and the like can also be targeted. These oil components may be used alone or in combination of two or more. The content of the emulsifier in the oil phase of the oily composition used in the present invention is preferably 0.5 to 50.
%, More preferably 1 to 30% by weight.
【0020】また、本発明に用いられる油性組成物の油
相には、公知の防腐剤、着色料又は香料等の添加剤を添
加することができる。該添加剤を添加する場合、その添
加量は、油性組成物の油相の全重量に対して、好ましく
は0.01〜5重量%である。本発明に用いられる油性
組成物においては、油相に油溶性有効物質を含有させて
もよい。上記油溶性有効物質とは、例えば、抗酸化剤、
栄養強化剤、薬剤及び動植物抽出物質が挙げられ、具体
的には、ミックストコフェロール、dl−α−トコフェ
ロ−ル、酢酸−dl−α−トコフェロ−ル、トコトリエ
ノール、EPA、DHA、ゴマ油抽出物、β−カロチ
ン、ビタミンA、ローズマリー油、ビタミンD類、ビタ
ミンK類、必須脂肪酸、米ぬか油抽出物、γ−オリザノ
ール、センブリエキス、プロポリス抽出物、セージ抽出
物、ペパー抽出物、スクワレン、スッポンオイル、肝油
等が挙げられる。上記油溶性有効物質は、単独で用いて
もよく、また2種以上を組み合わせて用いてもよい。上
記油溶性有効物質を油相に含有させる場合、その含有量
は、油相の全重量に対しては、好ましくは0.1〜99
重量%であり、更に好ましくは0.2〜40重量%であ
る。The oil phase of the oily composition used in the present invention may contain known additives such as preservatives, coloring agents and fragrances. When the additive is added, the amount of the additive is preferably 0.01 to 5% by weight based on the total weight of the oil phase of the oily composition. In the oily composition used in the present invention, the oil phase may contain an oil-soluble active substance. The oil-soluble active substance, for example, antioxidants,
Nutrient enhancers, drugs and animal and plant extracts; specifically, mixed tocopherol, dl-α-tocopherol, acetate-dl-α-tocopherol, tocotrienol, EPA, DHA, sesame oil extract, β -Carotene, vitamin A, rosemary oil, vitamin Ds, vitamin Ks, essential fatty acids, rice bran oil extract, γ-oryzanol, assembly extract, propolis extract, sage extract, pepper extract, squalene, terrapin oil, Liver oil and the like. The oil-soluble active substances may be used alone or in combination of two or more. When the oil-soluble active substance is contained in the oil phase, its content is preferably 0.1 to 99% based on the total weight of the oil phase.
%, More preferably 0.2 to 40% by weight.
【0021】本発明に用いられる油性組成物は、上記固
体相を5〜75重量%、好ましくは10〜60重量%、
上記油相を95〜25重量%、好ましくは90〜40重
量%含有するものがよい。The oily composition used in the present invention contains the solid phase in an amount of 5 to 75% by weight, preferably 10 to 60% by weight,
It is preferable that the oil phase contains 95 to 25% by weight, preferably 90 to 40% by weight.
【0022】本発明に用いられる油性組成物の製造方法
には特に制限はないが、例えば、後述する方法によって
製造することができる。本発明に用いられる油性組成物
の製造方法は、水性有効物質、水溶性フィルム形成剤、
水を含有する水相を10〜90℃に調整し、該水相と、
油性成分及び乳化剤を含有する油相とを混合して最終的
にW/O乳化物とし、次いで固体相中の水分含有量又は
アルコール水溶液含有量が30重量%以下となるように
乾燥処理することからなる。また、多価アルコール、増
粘安定剤、一価アルコール等を添加する場合は、上記水
相に混合溶解する。上記水性有効物質、水溶性フィルム
形成剤、多価アルコール、増粘安定剤、水、一価アルコ
ール、油性成分及び乳化剤としては、本発明に用いられ
る油性組成物に含有されるものと同様のものが用いられ
る。本発明に用いられる油性組成物の製造方法において
は、先ず水性有効物質、水溶性フィルム形成剤を水に混
合し水相とする。上記水相に、水溶性フィルム形成剤、
多価アルコール、増粘安定剤、一価アルコール等を添加
する場合は、ここで水相に混合する。また、上記水相に
は、本発明に用いられる油性組成物の固体相に含有させ
ることができる添加剤等を添加してもよい。次いで、上
記水相を10〜90℃の温度に調整する。また、乳化剤
及び油性成分を混合して油相とする。該油相中の乳化剤
の混合割合は、油相の全重量に対して、0.5〜50重
量%であることが好ましく、1〜30重量であることが
更に好ましい。また、上記油相には、本発明に用いられ
る油性組成物の油相に含有させることができる油性有効
物質及び添加剤等を添加してもよい。次いで、上記油相
と、上記水相を混合して最終的にW/O型乳化物とす
る。この場合、上記油相も10から90℃の温度に調整
することが好ましい。油相を加温することにより、常温
で固体状態の油性成分を添加することが可能となる。ま
た、上記水相及び上記油相の混合割合(上記水相の重量
部/上記油相の重量部)は、好ましくは95/5〜1/
99であり、更に好ましくは、85/15〜20/80
である。The method for producing the oily composition used in the present invention is not particularly limited. For example, it can be produced by the method described below. The method for producing the oily composition used in the present invention is an aqueous active substance, a water-soluble film forming agent,
Adjusting the aqueous phase containing water to 10-90 ° C.,
Mixing the oily component and an oil phase containing an emulsifier into a final W / O emulsion, and then subjecting the solid phase to a drying treatment so that the water content or the aqueous alcohol solution content is 30% by weight or less. Consists of When a polyhydric alcohol, a thickening stabilizer, a monohydric alcohol, or the like is added, the polyhydric alcohol is mixed and dissolved in the aqueous phase. The above-mentioned aqueous active substance, water-soluble film-forming agent, polyhydric alcohol, thickening stabilizer, water, monohydric alcohol, oily component and emulsifier are the same as those contained in the oily composition used in the present invention. Is used. In the method for producing an oily composition used in the present invention, first, an aqueous active substance and a water-soluble film forming agent are mixed with water to form an aqueous phase. In the aqueous phase, a water-soluble film forming agent,
When adding a polyhydric alcohol, a thickening stabilizer, a monohydric alcohol, or the like, they are mixed with the aqueous phase here. In addition, an additive or the like that can be contained in the solid phase of the oily composition used in the present invention may be added to the aqueous phase. Next, the aqueous phase is adjusted to a temperature of 10 to 90C. Further, an emulsifier and an oil component are mixed to form an oil phase. The mixing ratio of the emulsifier in the oil phase is preferably from 0.5 to 50% by weight, more preferably from 1 to 30% by weight, based on the total weight of the oil phase. Further, an oily effective substance, an additive, and the like that can be contained in the oil phase of the oil composition used in the present invention may be added to the oil phase. Next, the oil phase and the aqueous phase are mixed to finally form a W / O emulsion. In this case, it is preferable to adjust the oil phase to a temperature of 10 to 90 ° C. By heating the oil phase, it becomes possible to add an oil component in a solid state at normal temperature. The mixing ratio of the aqueous phase and the oil phase (parts by weight of the aqueous phase / parts by weight of the oil phase) is preferably 95/5 to 1/95.
99, more preferably 85/15 to 20/80.
It is.
【0023】上記水相と油相との混合物を最終的にW/
O型乳化物とする方法としては、従来公知の方法を特に
制限なく用いることができ、例えば、上記水相と油相と
の混合物を、プロペラ、ホモミキサー、ホモディスパ
ー、高圧ホモジナイザー、マイクロフルイダイザー等の
乳化機を用いて乳化する方法が挙げられる。次いで、上
記W/O型乳化物を、乾燥処理することにより、固体相
中の水分含有量又はアルコール水溶液含有量が30重量
%以下、好ましくは0〜20重量%、さらに好ましくは
0〜10重量%、最も好ましくは0〜5重量%となるよ
う処理し、油性組成物とする。このように親油性乳化剤
が水相まわりに密に配列したW/O型乳化物を乾燥して
固体相を形成させると、親油性乳化剤の親水性部分が固
体相に取り込まれた形で固体相のまわりに密に配列する
ため、固体相の油中での分散安定性が非常に高くなると
考えられる。上記W/O型乳化物を、乾燥する方法とし
てはに特に制限されないが、例えば、減圧乾燥、加熱乾
燥、薄膜蒸留乾燥及び凍結乾燥等の方法が挙げられる。
また、上記W/O型乳化物を加温したままの状態で行っ
てもよく、上記W/O型乳化物を冷蔵温度〜室温まで冷
却した後に行ってもよい。The mixture of the water phase and the oil phase is finally mixed with W /
As a method for preparing an O-type emulsion, a conventionally known method can be used without any particular limitation. For example, a mixture of the above-mentioned water phase and oil phase is treated with a propeller, a homomixer, a homodisper, a high-pressure homogenizer, a microfluidizer. And the like, emulsification using an emulsifier. Then, the W / O emulsion is subjected to a drying treatment so that the water content or the aqueous alcohol solution content in the solid phase is 30% by weight or less, preferably 0 to 20% by weight, more preferably 0 to 10% by weight. %, Most preferably from 0 to 5% by weight, to give an oily composition. When the W / O emulsion in which the lipophilic emulsifier is densely arranged around the aqueous phase is dried to form a solid phase, the solid phase is formed in a state where the hydrophilic portion of the lipophilic emulsifier is incorporated in the solid phase. , It is considered that the dispersion stability of the solid phase in oil becomes very high. The method for drying the W / O emulsion is not particularly limited, and examples thereof include methods such as vacuum drying, heat drying, thin film distillation drying, and freeze drying.
Moreover, you may carry out in the state which warmed the said W / O type emulsion, and may perform after cooling the said W / O type emulsion to refrigeration temperature-room temperature.
【0024】次に、本発明の粉末組成物について詳述す
る。本発明の粉末組成物は、水性有効物質を含有する上
記油性組成物と粉末化基材、場合によって乳化剤とから
なるもので、油性組成物を粉末化基材に吸着又は内包さ
せたものである。本発明の粉末組成物は、先に説明した
油性組成物を1〜80重量%、好ましくは5〜60重量
%、より好ましくは10〜50重量%含有し、上記粉末
化基材を99〜20重量%、好ましくは95〜40重量
%、より好ましくは90〜50重量%を含有する。Next, the powder composition of the present invention will be described in detail. The powder composition of the present invention comprises the above oily composition containing an aqueous effective substance and a powdered base material, and optionally an emulsifier, and is obtained by adsorbing or including the oily composition on the powdered base material. . The powder composition of the present invention contains the oily composition described above in an amount of 1 to 80% by weight, preferably 5 to 60% by weight, more preferably 10 to 50% by weight. % By weight, preferably 95 to 40% by weight, more preferably 90 to 50% by weight.
【0025】本発明の粉末化組成物の粉末化基材は、油
を吸着又は内包させることのできる物質で、澱粉、澱粉
加水分解物、サイクロデキストリン、蛋白、蛋白加水分
解物、複合蛋白質、加工澱粉、多価アルコール、アラビ
アガム、増粘安定剤、澱粉微生物培養物、ヘミセルロー
ス、水溶性皮膜形成合成高分子等が挙げられる。上記粉
末化基材は、単独で用いてもよく、又は2種以上を組み
合わせて用いてもよい。上記粉末化基材として用いられ
る澱粉、澱粉加水分解物、サイクロデキストリン、蛋
白、蛋白加水分解物、複合蛋白質は、例えば、コーン澱
粉、馬鈴薯澱粉、小麦澱粉、米澱粉、タピオカ澱粉、又
はこれら澱粉の加水分解物、α−サイクロデキストリ
ン、コーン蛋白、大豆蛋白、カゼインナトリウム、糖蛋
白、脱脂乳、及びこれら蛋白の加水分解物、ゼラチン、
にかわ、小麦グルテン加水分解物、レシチン蛋白複合体
等が挙げられる。上記粉末化基材に用いられる加工澱粉
は、澱粉又は澱粉加水分解物を加工処理したもので、例
えば、酸化澱粉、一澱粉リン酸エステル、二澱粉リン酸
エステル、リン酸化二澱粉リン酸エステル、アセチル化
二澱粉リン酸エステル、アセチル化澱粉、アセチル化二
澱粉アジピン酸、ヒドロキシプロピル二澱粉リン酸エス
テル、オクテニルコハク酸澱粉ナトリウム、オクテニル
コハク酸澱粉加水分解物ナトリウム等である。上記粉末
化基材に用いられる多価アルコールは、先に述べた油性
組成物に用いることができる多価アルコールと同じもの
を用いることができる。上記粉末化基材に用いられる増
粘安定剤は、例えば、キサンタンガム、グアーガム、ロ
ーカストビーンガム、カラギーナン、寒天、ペクチン、
アルギン酸ナトリウム、ジェランガム等が挙げられる。
上記粉末化基材に用いられる澱粉微生物培養物は、先に
述べた油性組成物に用いることができる澱粉微生物培養
物と同じものを用いることができる。上記粉末化基材に
用いられるヘミセルロースは、先に述べた油性組成物に
用いることができるヘミセルロースと同じものを用いる
ことができる。上記粉末化基材に用いられる水溶性皮膜
形成合成高分子は、先に述べた油性組成物に用いること
ができる水溶性皮膜形成合成高分子と同じものを用いる
ことができる。上記、粉末化基材は、単独で用いてもよ
く、又は2種以上を組み合わせて用いてもよい。上記粉
末化基材の含有量は、粉末状組成物全重量に対して、2
0〜99重量%、好ましくは40〜95重量%、さらに
好ましくは50〜90重量%である。The powdered base material of the powdered composition of the present invention is a substance capable of adsorbing or encapsulating oil, such as starch, starch hydrolyzate, cyclodextrin, protein, protein hydrolyzate, complex protein, and processed protein. Examples include starch, polyhydric alcohol, gum arabic, thickening stabilizer, starch microbial culture, hemicellulose, water-soluble film-forming synthetic polymer, and the like. The powdered base material may be used alone, or two or more kinds may be used in combination. The starch, starch hydrolyzate, cyclodextrin, protein, protein hydrolyzate, and composite protein used as the powdered base are, for example, corn starch, potato starch, wheat starch, rice starch, tapioca starch, or a mixture of these starches. Hydrolyzate, α-cyclodextrin, corn protein, soy protein, sodium caseinate, glycoprotein, skim milk, and hydrolyzate of these proteins, gelatin,
Glue, wheat gluten hydrolyzate, lecithin protein complex and the like. The processed starch used for the powdered base material is obtained by processing starch or starch hydrolyzate, for example, oxidized starch, monostarch phosphate, distarch phosphate, phosphorylated distarch phosphate, Acetylated starch diester, acetylated starch, acetylated distarch adipic acid, hydroxypropyl distarch phosphate, sodium octenylsuccinate starch, sodium octenylsuccinate starch hydrolyzate, and the like. As the polyhydric alcohol used for the powdered base material, the same polyhydric alcohol that can be used for the above-described oily composition can be used. Thickening stabilizers used in the powdered base material include, for example, xanthan gum, guar gum, locust bean gum, carrageenan, agar, pectin,
Sodium alginate, gellan gum and the like.
The same starch microbial culture that can be used in the oily composition described above can be used as the starch microbial culture used for the powdered substrate. The same hemicellulose that can be used for the above-described oily composition can be used as the hemicellulose used for the powdered base material. As the water-soluble film-forming synthetic polymer used for the powdered base material, the same water-soluble film-forming synthetic polymer that can be used for the oil-based composition described above can be used. The above powdered base materials may be used alone or in combination of two or more. The content of the powdered base material is 2% based on the total weight of the powdery composition.
It is from 0 to 99% by weight, preferably from 40 to 95% by weight, more preferably from 50 to 90% by weight.
【0026】また、粉末組成物に、乳化剤を配合させる
ことにより、さらに流動性及び水分散性の良いものを得
ることができる。該乳化剤は、先に述べた油性組成物に
用いることができるHLB10以下の乳化剤及びHLB
10以上の乳化剤と同じものを用いることができる。上
記乳化剤は、単独で用いてもよく、又は2種以上を組み
合わせて用いてもよい。該乳化剤の好ましい配合量は、
粉末状組成物全重量に対して、0.01〜15重量%、
好ましくは0.01〜10重量%である。Further, by blending an emulsifier with the powder composition, a powder composition having better fluidity and water dispersibility can be obtained. The emulsifier is an emulsifier having an HLB of 10 or less and an HLB which can be used for the oily composition described above.
The same thing as ten or more emulsifiers can be used. The emulsifiers may be used alone or in combination of two or more. A preferred amount of the emulsifier is
0.01 to 15% by weight based on the total weight of the powdery composition,
Preferably it is 0.01 to 10% by weight.
【0027】更に、本発明品の粉末組成物には、公知の
粉末流動性向上剤(乳酸カルシウムやシリカゲル等)、
着色料、香料、pH調整剤等を配合又は添加することが
できる。該添加剤を添加する場合、その配合又は添加量
は、粉末重量に対して、好ましくは0.01〜5重量%
である。The powder composition of the present invention may further contain a known powder fluidity improver (such as calcium lactate or silica gel),
Coloring agents, fragrances, pH adjusters and the like can be blended or added. When the additive is added, the amount of the additive is preferably 0.01 to 5% by weight based on the weight of the powder.
It is.
【0028】本発明の乳化組成物の製造方法には特に制
限はないが、例えば、後述する方法によって製造するこ
とができる。上記粉末化基材を水に溶解ないし分散させ
た後、水性有効物質を含有する上記油性組成物を加え、
プロペラ、ホモミキサー、ホモディスパー、高圧ホモジ
ナイザー、マイクロフルイダイザー等の乳化機を用い
て、油性組成物を内相、粉末化基材溶液を外相とする乳
化液を調製する。乳化時の温度は、10〜90℃に調整
されているのが好ましい。この乳化液を、減圧乾燥、加
熱乾燥、薄膜蒸留乾燥及び凍結乾燥等の方法を用いて水
分を蒸発させることにより本発明の粉末組成物を得る。
ここで、HLB10以下の乳化剤を添加する場合は、該
乳化剤を油性組成物に添加するのが好ましく、HLB1
0以上の乳化剤を添加する場合は、水に添加するのが好
ましい。上記油性組成物及び上記粉末化基材の混合割合
(上記油性組成物の重量部/上記粉末化基材の重量部)
は、1/99〜80/20であり、好ましくは、5/9
5〜60/40であり、さらに好ましくは10/90〜
50/50である。また、簡便な製造法として、次に述
べる粉体吸着法が挙げられる。上記粉末化基材を、ホバ
ートミキサー、ヘンシェルミキサー等の攪拌機に投入
後、流動している粉末化基材中に、上記油性組成物をゆ
っくり投入、混合することにより、本発明の粉末組成物
を得る。The method for producing the emulsified composition of the present invention is not particularly limited. For example, it can be produced by the method described below. After dissolving or dispersing the powdered base material in water, adding the oily composition containing an aqueous active substance,
Using an emulsifier such as a propeller, a homomixer, a homodisper, a high-pressure homogenizer, and a microfluidizer, an emulsion is prepared in which the oily composition is used as an internal phase and the powdered base material solution is used as an external phase. The temperature at the time of emulsification is preferably adjusted to 10 to 90 ° C. The powder composition of the present invention is obtained by evaporating water from the emulsion using a method such as drying under reduced pressure, drying by heating, drying by thin-film distillation, and freeze-drying.
Here, when an emulsifier having an HLB of 10 or less is added, the emulsifier is preferably added to the oily composition.
When 0 or more emulsifiers are added, they are preferably added to water. Mixing ratio of the oily composition and the powdered substrate (parts by weight of the oily composition / parts by weight of the powdered substrate)
Is 1/99 to 80/20, preferably 5/9
5/60/40, more preferably 10/90 ~
50/50. Further, as a simple production method, a powder adsorption method described below can be mentioned. After the powdered base material is charged into a stirrer such as a Hobart mixer or a Henschel mixer, the oily composition is slowly charged and mixed into the flowing powdered base material to thereby mix the powdered composition of the present invention. obtain.
【0029】本発明の粉末組成物は、水及び/又は一価
アルコールで希釈した状態や、そのままの状態で食品、
飼料、化粧品、工業製品、医薬品等に用いることができ
る。本発明の粉末組成物は、ラーメン、タンメン、うど
ん、そば、マカロニ、スパゲティ、フライ麺、ノンフラ
イ麺等の麺や、粉末及び液状スープ、たれ、ヨーグル
ト、調製乳、育児粉乳、アイスクリーム、ヨーグルト、
クリーム、ホイップクリーム等の乳製品、せんべい、ス
ナック、ビスケット、ウエハース、チョコレート、飴、
キャラメル、ガム、キャンディー、グミ等の菓子類、ち
くわ、かまぼこ、魚肉ソーセージ、魚肉ハム等の水産練
り製品、冷凍天ぷら、冷凍唐揚げ、冷凍フライ、冷凍餃
子、冷凍シュウマイ等の冷凍食品、みそ、ハンバーグ、
ハム、ソーセージ、餃子、シュウマイ、パン、食用油、
バター、マーガリン、ショートニング、チーズ、マヨネ
ーズ、ドレッシング、飲料、健康食品、治療食等の食
品、口紅、化粧用クリーム、乳液、シャンプー、リン
ス、パック剤、パップ剤等の化粧品、栄養ドリンク剤、
粉末薬、錠剤薬、軟膏、ビタミン薬等の医薬品及び医薬
部外品、肥料、潤滑油等の工業製品、その他飼料等に用
いることができる。[0029] The powder composition of the present invention can be prepared by diluting water or / and a monohydric alcohol,
It can be used for feed, cosmetics, industrial products, pharmaceuticals and the like. The powder composition of the present invention includes noodles such as ramen, tanmen, udon, buckwheat, macaroni, spaghetti, fried noodles, non-fried noodles, powders and liquid soups, sauces, yogurt, prepared milk, infant milk powder, ice cream, yogurt,
Dairy products such as cream and whipped cream, rice crackers, snacks, biscuits, wafers, chocolate, candy,
Caramel, gum, candy, gummy and other confectionery, chikuwa, kamaboko, fish meat sausage, fish meat ham and other fishery products, frozen tempura, frozen deep-fried, frozen fried, frozen dumplings, frozen dumplings and other frozen foods, miso, hamburger,
Ham, sausage, gyoza, shumai, bread, cooking oil,
Butter, margarine, shortening, cheese, mayonnaise, dressing, beverages, health foods, foods such as therapeutic foods, lipsticks, cosmetic creams, emulsions, shampoos, rinses, packs, cataplasms, etc., nutrition drinks,
It can be used for pharmaceuticals such as powders, tablets, ointments and vitamins and quasi-drugs, industrial products such as fertilizers and lubricating oils, and other feeds.
【0030】本発明の粉末組成物を水へ投入すると、水
性有効物質微粒子を含有する油粒子が分散した水溶液が
得られる。また、粉末組成物中の油性組成物中に分散す
る固体相の水溶性フィルム形成剤量を調整することによ
り、油性組成物が水に接触した時の水性有効物質の水中
への溶出量調整が可能となる。つまり、水溶性フィルム
形成剤が水性有効物質100重量部に対して水溶性フィ
ルム形成剤量が50重量部より少ない場合、好ましくは
25重量部より少ない場合、油性組成物から外部へ水性
有効物質が徐々に溶出する(徐放性効果)が、水性有効
物質100重量部に対して水溶性フィルム形成剤量が5
0重量部より多い場合、好ましくは80重量部、より好
ましくは100重量部より多い場合、油性組成物から外
部への水性有効物質の溶出をかなり抑える(溶出抑制効
果)ことができる。上記方法により徐放性効果を持たせ
た、旨味や甘み又は香りを有する水性有効物質を含有す
る本発明の粉末組成物は、徐々にその旨味や甘み又は香
りを外部へ放出するため、味の持続効果を有する。ま
た、上記方法により溶出抑制効果を持たせた、苦みや渋
みを有する水性有効物質を含有する本発明の粉末組成物
は、その味をほとんど感じないため、上記食品や医薬品
に利用しても苦みや渋みをほとんど感じない。本発明の
粉末組成物は、錠剤や顆粒状の形態にして健康食品や薬
としての利用もできる。本発明の粉末組成物は、公知の
カプセル剤(ゼラチンカプセルや寒天カプセル等)へ封
入した形態での利用も可能である。また、従来は、水性
有効物質と油性有効物質とは、別々に食品、飼料、化粧
品、工業製品、医薬品へ添加されていたが、本発明の乳
化組成物及び粉末組成物においては、水性有効物質と油
性有効物質とを両方同時に添加することが可能となる。
また、水性有効物質が水溶液状態でなく、固体状態とし
て油性成分に被覆されているため、水性有効物質自体の
劣化、分解、腐敗等を防止することができる。さらに、
水性有効物質が、固体状態で水溶性フィルムおよび油性
成分に被覆されているため、腸管で吸収される水性有効
物質を含有する本発明品を摂取した場合、摂取後に水性
有効物質に結合する吸収阻害物質や水性有効物質を消化
する消化管酵素から攻撃を受けにくい。したがって、水
性有効物質が活性を保持したまま腸管吸収部位まで輸送
されるため吸収率が向上する。When the powder composition of the present invention is poured into water, an aqueous solution in which oil particles containing fine particles of an aqueous active substance are dispersed is obtained. Further, by adjusting the amount of the water-soluble film-forming agent of the solid phase dispersed in the oily composition in the powder composition, the amount of the aqueous active substance dissolved in water when the oily composition comes into contact with water can be adjusted. It becomes possible. In other words, when the amount of the water-soluble film-forming agent is less than 50 parts by weight, preferably less than 25 parts by weight, based on 100 parts by weight of the aqueous active substance, the aqueous active substance is discharged from the oily composition to the outside. It is gradually eluted (sustained release effect), but the amount of the water-soluble film forming agent is 5 per 100 parts by weight of the aqueous active substance.
When the amount is more than 0 parts by weight, preferably 80 parts by weight, more preferably more than 100 parts by weight, the dissolution of the aqueous active substance from the oily composition to the outside can be considerably suppressed (elution suppressing effect). The powder composition of the present invention containing the aqueous active substance having umami, sweetness or aroma, which has a sustained release effect by the above method, gradually releases the umami, sweetness or aroma to the outside, and has a Has a lasting effect. In addition, the powder composition of the present invention containing an aqueous active substance having bitterness and astringency, which has an elution suppressing effect by the above method, hardly feels its taste, so that it can be used in the foods and pharmaceuticals. I feel little bitterness. The powder composition of the present invention can be used as a health food or medicine in the form of tablets or granules. The powder composition of the present invention can be used in the form of being encapsulated in known capsules (eg, gelatin capsules and agar capsules). Conventionally, aqueous active substances and oily active substances have been separately added to foods, feeds, cosmetics, industrial products, and pharmaceuticals.However, in the emulsified composition and powder composition of the present invention, aqueous active substances And the oily active substance can be added at the same time.
In addition, since the aqueous effective substance is coated with the oily component in a solid state instead of an aqueous state, deterioration, decomposition, decay, etc. of the aqueous effective substance itself can be prevented. further,
Since the aqueous active substance is coated with the water-soluble film and the oily component in a solid state, when the product of the present invention containing the aqueous active substance that is absorbed in the intestinal tract is ingested, absorption inhibition that binds to the aqueous active substance after ingestion is suppressed. Less susceptible to gastrointestinal enzymes that digest substances and aqueous active substances. Therefore, the absorption rate is improved because the aqueous active substance is transported to the intestinal absorption site while maintaining the activity.
【0031】[0031]
固体相中の水性有効物質含有量(重量%)=(水性有効
物質重量/(油性組成物中の水又はアルコール水溶液重
量+水又はアルコール水溶液を除いた固体相重量))×
100 〔固体相中の水溶性フィルム形成剤含有量〕 固体相中の水溶性フィルム形成剤含有量(重量%)=
(水溶性フィルム形成剤重量/(油性組成物中の水又は
アルコール水溶液重量+水又はアルコール水溶液を除い
た固体相重量))×100 〔固体相中の多価アルコール含有量〕 固体相中の多価アルコール含有量(重量%)=(多価ア
ルコール重量(固形分)/(油性組成物中の水又はアル
コール水溶液重量+水又はアルコール水溶液を除いた固
体相重量))×100 〔固体相の平均粒子径〕油性組成物の固体相の平均粒子
径は、レーザー回折式粒度分布測定装置(LA−500
型、株式会社堀場製作所製)を用いて測定した。Content of aqueous active substance in solid phase (% by weight) = (weight of aqueous active substance / (weight of water or alcohol aqueous solution in oily composition + weight of solid phase excluding water or alcohol aqueous solution)) ×
100 [Water-soluble film-forming agent content in solid phase] Water-soluble film-forming agent content in solid phase (% by weight) =
(Water-soluble film-forming agent weight / (Water or alcohol aqueous solution in oily composition + Solid phase weight excluding water or alcohol aqueous solution)) × 100 [Polyhydric alcohol content in solid phase] Polyhydric alcohol content (% by weight) = (weight of polyhydric alcohol (solid content) / (weight of water or alcohol aqueous solution in oily composition + weight of solid phase excluding water or alcohol aqueous solution)) × 100 [average of solid phase] Particle diameter] The average particle diameter of the solid phase of the oily composition is measured by a laser diffraction particle size distribution analyzer (LA-500).
Mold, manufactured by Horiba, Ltd.).
【0032】参考例1 霊芝エキス末70.0g、ゼラチン(宮城化学工業
(株)製、ゼラチンA−U)30.0g、水520.0
gを混合して60℃に加温したものを水相とし、大豆油
350.0g、テトラグリセリントリステアレート(阪
本薬品工業(株)製、SYグリスターTS−310、H
LB:4)30.0gを混合して60℃で溶解させたも
のを油相とした。この油相に前記水相をゆっくり添加し
ながらホモミキサーを用いて6000rpmで20分間、
60℃で混合乳化することによりW/O乳化物を得た。
次いで、得られた乳化物をオイルポンプを用いて減圧脱
水することにより、霊芝エキスを14.5重量%含有す
る液状茶色の油性組成物を得た。油性組成物中の水分含
有量は0.5重量%であった。油相中に分散している固
体相中の水分含有量は2.3重量%、霊芝エキスの含有
量は68.4重量%で、霊芝エキス100重量部に対す
るゼラチンの量は42.9重量部であった。また、固体
相中のゼラチン含有量は29.3重量%であった。固体
相の平均粒子径は1.2μmであった。得られた油性組
成物の保存安定性について、以下に示す方法により評価
を行った。評価結果を表1に示す。Reference Example 1 Reishi extract powder 70.0 g, gelatin (manufactured by Miyagi Chemical Industry Co., Ltd., gelatin AU) 30.0 g, water 520.0
g and heated to 60 ° C. to obtain an aqueous phase, 350.0 g of soybean oil, tetraglycerin tristearate (manufactured by Sakamoto Pharmaceutical Co., Ltd., SY Glister TS-310, H
LB: 4) 30.0 g was mixed and dissolved at 60 ° C. to obtain an oil phase. While slowly adding the aqueous phase to the oil phase, using a homomixer at 6000 rpm for 20 minutes,
A W / O emulsion was obtained by mixing and emulsifying at 60 ° C.
Next, the obtained emulsion was dehydrated under reduced pressure using an oil pump to obtain a liquid brown oily composition containing 14.5% by weight of Reishi extract. The water content in the oily composition was 0.5% by weight. The water content in the solid phase dispersed in the oil phase is 2.3% by weight, the content of Ganoderma extract is 68.4% by weight, and the amount of gelatin relative to 100 parts by weight of Ganoderma extract is 42.9. Parts by weight. The gelatin content in the solid phase was 29.3% by weight. The average particle size of the solid phase was 1.2 μm. The storage stability of the obtained oily composition was evaluated by the following method. Table 1 shows the evaluation results.
【0033】〔油性組成物の保存安定性〕得られた油性
組成物を、5℃及び40℃の恒温槽に入れ、1ヶ月、3
ヶ月及び6ヶ月保存した後の油性組成物の外観を肉眼で
観察した。また、油性組成物を、室温に、1ヶ月、3ヶ
月及び6ヶ月保存した後の油性組成物の外観の肉眼によ
る観察も行った。それぞれ、下記評価基準に従って評価
を行った。なお、製造直後の肉眼観察についても表に記
載した。 ◎:油性組成物に異常が全く認められなかった。 ○:全体積の1%未満の油相分離が認められた。 △:全体積の1〜5%の油相分離が認められた。 ▲:全体積の5%以上の油相分離が認められた。 □:全体積の1%未満の固体相(又は水相)分離が認め
られた。 ■:全体積の1%以上の固体相(又は水相)分離が認め
られた。 ×:カビが発生した。[Storage stability of oily composition] The obtained oily composition was placed in a thermostat at 5 ° C and 40 ° C for 1 month and 3 months.
The appearance of the oil composition after storage for 1 month and 6 months was visually observed. The appearance of the oily composition after storing the oily composition at room temperature for 1 month, 3 months, and 6 months was also visually observed. Each was evaluated according to the following evaluation criteria. The table also shows the visual observations immediately after production. A: No abnormality was observed in the oily composition. :: Oil phase separation of less than 1% of the total volume was observed. Δ: Oil phase separation of 1 to 5% of the total volume was observed. :: Oil phase separation of 5% or more of the total volume was observed. □: Solid phase (or aqueous phase) separation of less than 1% of the total volume was observed. (2): Solid phase (or aqueous phase) separation of 1% or more of the total volume was observed. X: Mold occurred.
【0034】参考例2 霊芝エキス末70.0g、ゼラチンA−U、120.0
g、水430.0gを混合して60℃に加温したものを
水相とし、大豆油350.0g、SYグリスターTS−
310、30.0gを混合して60℃で溶解させたもの
を油相とした。以下参考例1の方法と同様にして霊芝エ
キス12.3重量%を含有する液状茶色の油性組成物を
得た。油性組成物中の水分含有量は0重量%であった。
油相中に分散している固体相中の水分含有量は0重量
%、霊芝エキスの含有量は36.8重量%で、霊芝エキ
ス100重量部に対するゼラチンの量は171.4重量
部であった。また、固体相中のゼラチン含有量は63.
2重量%であった。固体相の平均粒子径は0.9μmで
あった。得られた油性組成物の保存安定性について、参
考例1と同様の評価を行った。評価結果を表1に示す。Reference Example 2 Reishi extract powder 70.0 g, Gelatin AU, 120.0 g
g, 430.0 g of water and heated to 60 ° C. to form an aqueous phase, 350.0 g of soybean oil, SY Glister TS-
An oil phase was obtained by mixing 310 and 30.0 g and dissolving at 60 ° C. In the same manner as in Reference Example 1, a liquid brown oily composition containing 12.3% by weight of Reishi extract was obtained. The water content in the oily composition was 0% by weight.
The water content in the solid phase dispersed in the oil phase was 0% by weight, the content of Ganoderma extract was 36.8% by weight, and the amount of gelatin was 171.4 parts by weight based on 100 parts by weight of Ganoderma extract. Met. The gelatin content in the solid phase was 63.
It was 2% by weight. The average particle size of the solid phase was 0.9 μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0035】参考例3 霊芝エキス末70.0g、ゼラチンA−U、120.0
g、D−ソルビトール液(東和化成工業(株)製、ソル
ビットL−70、水分含有量:30重量%)70.0
g、水360.0gを混合して60℃に加温したものを
水相とし、大豆油350.0g、SYグリスターTS−
310、30.0gを混合して60℃で溶解させたもの
を油相とした。以下参考例1の方法と同様にして霊芝エ
キス11.2重量%含有する液状茶色の油性組成物を得
た。油性組成物中の水分含有量は0.6重量%であっ
た。油相中に分散している固体相中の水分含有量は1.
5重量%、霊芝エキスの含有量は28.8重量%で、霊
芝エキス100重量部に対するゼラチンの量は171.
4重量部であった。また、固体相中のゼラチン含有量は
49.4重量%、D−ソルビット含有量は20.2重量
%であった。固体相の平均粒子径は0.6μmであっ
た。得られた油性組成物の保存安定性について、参考例
1と同様の評価を行った。評価結果を表1に示す。Reference Example 3 Reishi extract powder 70.0 g, gelatin AU, 120.0 g
g, D-sorbitol solution (manufactured by Towa Chemical Industry Co., Ltd., sorbit L-70, water content: 30% by weight) 70.0
g, water (360.0 g) and heated to 60 ° C. to form an aqueous phase, soybean oil (350.0 g), SY Glister TS-
An oil phase was obtained by mixing 310 and 30.0 g and dissolving at 60 ° C. In the same manner as in Reference Example 1, a liquid brown oily composition containing 11.2% by weight of Reishi extract was obtained. The water content in the oily composition was 0.6% by weight. The water content in the solid phase dispersed in the oil phase is 1.
5 wt%, the content of Ganoderma extract was 28.8% by weight, and the amount of gelatin per 100 parts by weight of Ganoderma extract was 171.
It was 4 parts by weight. The gelatin content in the solid phase was 49.4% by weight, and the D-sorbitol content was 20.2% by weight. The average particle size of the solid phase was 0.6 μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0036】参考例4 グルタミン酸ナトリウム80.0g、水溶性大豆ファイ
バー(不二製油(株)製、ソヤファイブ−S)16.0
g、水454.0gを混合して60℃に加温したものを
水相とし、大豆油395.0g、大豆硬化油(日清製油
(株)製、大豆硬化油34°)5.0g、ポリグリセリ
ン縮合リシノレイン酸エステル(理研ビタミン(株)
製、ポエムPR−300、HLB:1.7)45.0g
及びグリセリン脂肪酸モノエステル(理研ビタミン
(株)製、エマルジーMU、HLB:4.2)5.0g
を混合して60℃で溶解させたものを油相とした。以下
参考例1の方法と同様にしてグルタミン酸ナトリウム1
4.2重量%含有する液状白色の油性組成物を得た。油
性組成物中の水分含有量は3.4重量%であった。油相
中に分散している固体相中の水分含有量は16.6重量
%、グルタミン酸ナトリウムの含有量は69.5重量%
で、グルタミン酸ナトリウム100重量部に対する水溶
性大豆ファイバーの量は20重量部であった。また、固
体相中の水溶性大豆ファイバー含有量は13.9重量%
であった。固体相の平均粒子径は0.5μmであった。
得られた油性組成物の保存安定性について、参考例1と
同様の評価を行った。評価結果を表1に示す。Reference Example 4 80.0 g of sodium glutamate, water-soluble soybean fiber (Soyafive-S, manufactured by Fuji Oil Co., Ltd.) 16.0
g, water (454.0 g) and heated to 60 ° C. to form an aqueous phase, soybean oil (395.0 g), soybean hardened oil (Nissin Oil Co., Ltd., soybean hardened oil (34 °), 5.0 g), Polyglycerin condensed ricinoleate (RIKEN Vitamin Co., Ltd.)
Manufactured by Poem PR-300, HLB: 1.7) 45.0 g
And 5.0 g of glycerin fatty acid monoester (Emulgy MU, HLB: 4.2, manufactured by Riken Vitamin Co., Ltd.)
Were dissolved at 60 ° C. to obtain an oil phase. Thereafter, sodium glutamate 1 was prepared in the same manner as in Reference Example 1.
A liquid white oily composition containing 4.2% by weight was obtained. The water content in the oily composition was 3.4% by weight. The water content in the solid phase dispersed in the oil phase is 16.6% by weight, and the content of sodium glutamate is 69.5% by weight.
The amount of the water-soluble soybean fiber was 100 parts by weight based on 100 parts by weight of sodium glutamate. The water-soluble soy fiber content in the solid phase was 13.9% by weight.
Met. The average particle size of the solid phase was 0.5 μm.
The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0037】参考例5 茶抽出物(太陽化学(株)製、サンフェノン)90.0
gとプルラン(林原(株)製、プルラン)80.0g、
グアーガム(三栄源エフ・エフ・アイ(株)製、ビスト
ップB−20)1.0g、水399.0gを混合して6
0℃に加温したものを水相とし、大豆油400.0g、
ヘキサグリセリンペンタオレート(阪本薬品工業(株)
製、SYグリスターPO−500、HLB:4)30.
0gを混合して60℃で溶解させたものを油相とした。
以下参考例1の方法と同様にして茶抽出物14.9重量
%を含有する液状茶色の油性組成物を得た。油性組成物
中の水分含有量は0.3重量%であった。油相中に分散
している固体相中の水分含有量は1.0重量%、茶抽出
物の含有量は52.1重量%で、茶抽出物100重量部
に対するプルランの量は88.9重量部であった。ま
た、固体相中のプルラン含有量は46.3重量%であっ
た。固体相の平均粒子径は0.4μmであった。得られ
た油性組成物の保存安定性について、参考例1と同様の
評価を行った。評価結果を表1に示すReference Example 5 Tea extract (Sanphenon, manufactured by Taiyo Kagaku Co., Ltd.) 90.0
g and pullulan (Pulllan manufactured by Hayashibara Co., Ltd.) 80.0 g,
A mixture of 1.0 g of guar gum (manufactured by Saneigen FFI Co., Ltd., Bistop B-20) and 399.0 g of water 6
What was heated to 0 ° C. was used as an aqueous phase, soybean oil 400.0 g,
Hexaglycerin pentaolate (Sakamoto Pharmaceutical Co., Ltd.)
Manufactured by SY Glister PO-500, HLB: 4) 30.
An oil phase was obtained by mixing and dissolving 0 g at 60 ° C.
Thereafter, a liquid brown oily composition containing 14.9% by weight of a tea extract was obtained in the same manner as in Reference Example 1. The water content in the oily composition was 0.3% by weight. The water content in the solid phase dispersed in the oil phase was 1.0% by weight, the content of the tea extract was 52.1% by weight, and the amount of pullulan per 100 parts by weight of the tea extract was 88.9. Parts by weight. The pullulan content in the solid phase was 46.3% by weight. The average particle size of the solid phase was 0.4 μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0038】参考例6 アスコルビン酸70.0g、ゼラチンA−U、70.0
g、水溶性コーンファイバー(日本食品化工(株)製、
セルエース#25)30.0g、酵素分解レシチン(日
清製油(株)、ベイシスLG−10K)1.0g、水4
29.0gを混合溶解したものを水相(60℃)とし、
中鎖脂肪酸トリグリセリド(日清製油(株)製、OD
O)300.0g、トコフェロール(日清製油(株)
製、トコフェロール100)50.0g、ポエムPR−
300、50.0gを混合して60℃で溶解させたもの
を油相とした。以下参考例1の方法と同様にしてアスコ
ルビン酸12.2重量%を含有する液状白色の油性組成
物を得た。油性組成物中の水分含有量は0.3重量%で
あった。油相中に分散している固体相中の水分含有量は
1.0重量%、アスコルビン酸含有量は、40.5重量
%、アスコルビン酸100重量部に対するゼラチン及び
コーンファイバーの量は142.9重量部であった。ま
た、固体相中のゼラチン及びコーンファイバー含有量は
57.9重量%であった。固体相の平均粒子径は0.8
μmであった。得られた油性組成物の保存安定性につい
て、参考例1と同様の評価を行った。評価結果を表1に
示す。Reference Example 6 70.0 g of ascorbic acid, gelatin AU, 70.0 g
g, water-soluble corn fiber (Nippon Shokuhin Kako Co., Ltd.)
Cell Ace # 25) 30.0 g, enzyme-degraded lecithin (Nisshin Oil Co., Ltd., Basis LG-10K) 1.0 g, water 4
An aqueous phase (60 ° C.) was obtained by mixing and dissolving 29.0 g,
Medium chain fatty acid triglyceride (OD, manufactured by Nisshin Oil Co., Ltd.)
O) 300.0 g, tocopherol (Nissin Oil Co., Ltd.)
Manufactured by Tocopherol 100), 50.0 g, Poem PR-
300 and 50.0 g were mixed and dissolved at 60 ° C. to obtain an oil phase. Thereafter, a liquid white oily composition containing 12.2% by weight of ascorbic acid was obtained in the same manner as in Reference Example 1. The water content in the oily composition was 0.3% by weight. The water content in the solid phase dispersed in the oil phase is 1.0% by weight, the ascorbic acid content is 40.5% by weight, and the amount of gelatin and corn fiber relative to 100 parts by weight of ascorbic acid is 142.9. Parts by weight. The content of gelatin and corn fiber in the solid phase was 57.9% by weight. The average particle size of the solid phase is 0.8
μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0039】参考例7 塩化カルシウム50.0g、ゼラチンA−U、100.
0g、還元澱粉糖化物液(東和化成工業(株)製、アマ
ミール、水分含有量:30重量%)30.0g、水46
0.0gを混合して60℃に加温したものを水相とし、
大豆油250.0g、精製魚油(タマ生化学(株)製、
DHA−27)50.0g、SYグリスターTS−31
0、10.0g、グリセリンジオレート50.0gを混
合して60℃で溶解させたものを油相とした。以下参考
例1の方法と同様にして塩化カルシウム9.8重量%を
含有する液状白色の油性組成物を得た。油性組成物中の
水分含有量は2.8重量%であった。油相中に分散して
いる固体相中の水分含有量は9.6重量%、塩化カルシ
ウムの含有量は33.2重量%で、塩化カルシウム10
0重量部に対するゼラチンの量は130重量部であっ
た。また、固体相中のゼラチン含有量は43.2重量
%、還元澱粉糖化物含有量は14.0重量%であった。
固体相の平均粒子径は0.7μmであった。得られた油
性組成物の保存安定性について、参考例1と同様の評価
を行った。評価結果を表1に示す。Reference Example 7 50.0 g of calcium chloride, gelatin AU, 100.
0 g, 30.0 g of reduced starch saccharified solution (Amamiru, water content: 30% by weight, manufactured by Towa Chemical Industry Co., Ltd.), water 46
The aqueous phase was obtained by mixing 0.0 g and heating to 60 ° C.
250.0 g of soybean oil, refined fish oil (manufactured by Tama Seikagaku Co., Ltd.
DHA-27) 50.0 g, SY Glister TS-31
An oil phase was prepared by mixing 0, 10.0 g and 50.0 g of glycerindiolate and dissolving at 60 ° C. Thereafter, a liquid white oily composition containing 9.8% by weight of calcium chloride was obtained in the same manner as in Reference Example 1. The water content in the oily composition was 2.8% by weight. The water content in the solid phase dispersed in the oil phase is 9.6% by weight, the content of calcium chloride is 33.2% by weight,
The amount of gelatin relative to 0 parts by weight was 130 parts by weight. The gelatin content in the solid phase was 43.2% by weight, and the reduced starch saccharified substance content was 14.0% by weight.
The average particle size of the solid phase was 0.7 μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0040】参考例8 高麗人参エキス80.0g、ゼラチン(新田ゼラチン
(株)製、ゼラチンMJ)55.0g、ソルビットL−
70、50.0g、10重量%エタノール水溶液51
7.0gを混合溶解したものを水相(60℃)とし、大
豆油250.0g、木ろう3.0g、ポエムPR−30
0、40.0g、クエン酸モノグリセライド(理研ビタ
ミン(株)製、ポエムK−30、HLB:3)5.0g
を混合して60℃で溶解させたものを油相とした。以下
参考例1の方法と同様にして17.1重量%の高麗人参
エキスを含有した液状茶色の油性組成物を得た。油性組
成物中の水分含有量は0.2重量%であった。油相中に
分散している固体相中の水分含有量は0.6重量%、高
麗人参エキス含有量は46.8重量%、高麗人参エキス
100重量部に対するゼラチン量は68.8重量部であ
った。また、固体相中のゼラチン含有量は32.2重量
%、D−ソルビット含有量は20.5重量%であった。
固体相の平均粒子径は1.2μmであった。得られた油
性組成物の保存安定性について、参考例1と同様の評価
を行った。評価結果を表1に示す。REFERENCE EXAMPLE 8 Ginseng extract 80.0 g, gelatin (manufactured by Nitta Gelatin Co., Ltd., gelatin MJ) 55.0 g, Sorbit L-
70, 50.0 g, 10% by weight aqueous ethanol solution 51
The aqueous phase (60 ° C.) obtained by mixing and dissolving 7.0 g was soy oil 250.0 g, wood wax 3.0 g, Poem PR-30.
0, 40.0 g, citrate monoglyceride (manufactured by Riken Vitamin Co., Ltd., Poem K-30, HLB: 3) 5.0 g
Were dissolved at 60 ° C. to obtain an oil phase. A liquid brown oily composition containing 17.1% by weight of ginseng extract was obtained in the same manner as in Reference Example 1. The water content in the oily composition was 0.2% by weight. The water content in the solid phase dispersed in the oil phase was 0.6% by weight, the content of ginseng extract was 46.8% by weight, and the amount of gelatin relative to 100 parts by weight of ginseng extract was 68.8 parts by weight. there were. The gelatin content in the solid phase was 32.2% by weight, and the D-sorbitol content was 20.5% by weight.
The average particle size of the solid phase was 1.2 μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0041】参考例9 ビタミンB140.0gとアラビアガム(三栄薬品貿易
(株)製、アラビックコールSS)60.0g、グリセ
リン200.0g、水370.0gを混合して60℃に
加温したものを水相とし、ODO、300.0g、SY
グリスターPO−500、30.0gを混合して60℃
で溶解させたものを油相とした。以下参考例1の方法と
同様にしてビタミンB16.3重量%を含有する液状で
半透明黄色の油性組成物を得た。油性組成物中の水分含
有量は0.1重量%であった。油相中に分散している固
体相中の水分含有量は0.2重量%、ビタミンB1の含
有量は13.3重量%で、ビタミンB1100重量部に
対するアラビアガムの量は150重量部であった。ま
た、固体相中のアラビアガム含有量は20.0重量%、
グリセリン含有量は66.5重量%であった。固体相の
平均粒子径は0.3μmであった。得られた油性組成物
の保存安定性について、参考例1と同様の評価を行っ
た。評価結果を表1に示す。[0041] Reference Example 9 vitamin B 1 40.0g and Arabic gum (Sanei chemical Trade Co., Ltd., Arabic call SS) 60.0g, glycerin 200.0g, a mixture of water 370.0g 60 ℃ to warming The water phase is used as the aqueous phase, ODO, 300.0 g, SY
Glister PO-500, 30.0 g, mixed at 60 ° C
The oily phase was used as the oil phase. Thereafter, a liquid translucent yellow oily composition containing 6.3% by weight of vitamin B 1 was obtained in the same manner as in Reference Example 1. The water content in the oily composition was 0.1% by weight. The water content of the solid phase dispersed in the oil phase is 0.2 wt%, the content of vitamin B 1 represents 13.3% by weight, the amount of gum arabic to vitamin B 1 100 parts by weight 150 parts by weight Department. The gum arabic content in the solid phase is 20.0% by weight,
The glycerin content was 66.5% by weight. The average particle size of the solid phase was 0.3 μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0042】参考例10 ビタミンB120.0g、アラビックコールSS、4
0.0g、テトラオレイン酸ポリオキシエチレン(40
モル)ソルビット(花王(株)製、レオドール440、
HLB:11.8)1.0g、グリセリン20.0g、
水504.0gを混合溶解したものを水相(60℃)と
し、トリ2−エチルヘキサン酸グリセリル(日清製油
(株)製、TIO)300.0g、流動パラフィン5
0.0g、スクワラン5.0g、ヘキサグリセリン縮合
リシノレイン酸エステル(阪本薬品工業(株)製、SY
グリスターCR−500、HLB:2)55.0g、水
添レシチン(日清製油(株)製、ベイシスLP−20
H)5.0gを混合して60℃で溶解させたものを油相
とした。この油相に前記水相をゆっくり添加しながらホ
モミキサーを用いて6000rpmで20分間、60℃で
混合乳化後、高圧ホモジナイザーを用いて100kg/cm
2の圧力で乳化処理することによりW/O乳化物を得
た。次いで、得られた乳化物をオイルポンプを用いて減
圧脱水することによりビタミンB1を4.0重量%を含
有した液状黄色の油性組成物を得た。油性組成物中の水
分含有量は0.2重量%であった。油相中に分散してい
る固体相中の水分含有量は1.2重量%、ビタミンB1
の含量は24.4重量%、ビタミンB1100重量部に
対するアラビアガムの量は200重量部であった。ま
た、固体相中のアラビアガム含有量は48.8重量%、
グリセリン含有量は24.4重量%であった。固体相の
平均粒子径は0.2μmであった。得られた油性組成物
の保存安定性について、参考例1と同様の評価を行っ
た。評価結果を表1に示す。Reference Example 10 Vitamin B 1 20.0 g, Arabic Cole SS, 4
0.0 g of polyoxyethylene tetraoleate (40
Mol) sorbit (manufactured by Kao Corporation, Leodor 440)
HLB: 11.8) 1.0 g, glycerin 20.0 g,
An aqueous phase (60 ° C.) obtained by mixing and dissolving 504.0 g of water was used as an aqueous phase (60 ° C.), 300.0 g of glyceryl tri-2-ethylhexanoate (TIO, manufactured by Nisshin Oil Co., Ltd.), and liquid paraffin 5
0.0 g, squalane 5.0 g, hexaglycerin condensed ricinoleate (manufactured by Sakamoto Pharmaceutical Co., Ltd., SY
55.0 g of Glyster CR-500, HLB: 2), hydrogenated lecithin (manufactured by Nisshin Oil Co., Ltd., Basis LP-20)
H) 5.0 g was mixed and dissolved at 60 ° C. to obtain an oil phase. While slowly adding the aqueous phase to the oil phase, the mixture was emulsified at 6000 rpm for 20 minutes at 60 ° C. using a homomixer, and then 100 kg / cm 2 using a high-pressure homogenizer.
By emulsifying at a pressure of 2, a W / O emulsion was obtained. Then, to obtain an oily liquid composition yellow containing vitamin B 1 4.0 wt% by the emulsion obtained are dehydrated under reduced pressure using an oil pump. The water content in the oily composition was 0.2% by weight. The water content in the solid phase dispersed in the oil phase is 1.2% by weight, and vitamin B 1
The content of 24.4 wt%, the amount of gum arabic to vitamin B 1 100 parts by weight was 200 parts by weight. The gum arabic content in the solid phase was 48.8% by weight,
The glycerin content was 24.4% by weight. The average particle size of the solid phase was 0.2 μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0043】参考例11 インスリン0.4g、ゼラチンA−U、4.0g、グリ
セリン2.0g、0.1N塩酸水溶液60.6gを混合
して30℃にしたものを水相とし、大豆油30.0g、
SYグリスターTS−310、3.0gを混合して30
℃で溶解させたものを油相とした。この油相に前記水相
をゆっくり添加しながらホモミキサーを用いて6000
rpmで10分間、30℃で混合乳化することによりW/
O乳化物を得た。次いで、得られた乳化物をオイルポン
プを用いて30℃で減圧脱水することにより、インスリ
ン1.0重量%含有する液状白色の油性組成物を得た。
油性組成物中の水分含有量は0.1重量%であった。油
相中に分散している固体相中の水分含有量は0.6重量
%、インスリンの含有量は6.2重量%で、インスリン
100重量部に対するゼラチンの量は1000重量部で
あった。また、固体相中のゼラチン含有量は62.1重
量%、グリセリン含有量は31.1重量%であった。固
体相の平均粒子径は1.8μmであった。得られた油性
組成物の保存安定性について、参考例1と同様の評価を
行った。評価結果を表1に示Reference Example 11 0.4 g of insulin, 4.0 g of gelatin A-U, 2.0 g of glycerin, and 60.6 g of 0.1N hydrochloric acid aqueous solution were mixed at 30 ° C. to obtain an aqueous phase. 0.0 g,
30 g of SY Glister TS-310 mixed with 3.0 g
What was melt | dissolved at C was made into the oil phase. While slowly adding the aqueous phase to the oil phase, use a homomixer to mix
By mixing and emulsifying at 30 ° C. for 10 minutes at rpm, W /
An O emulsion was obtained. Next, the obtained emulsion was dehydrated under reduced pressure at 30 ° C. using an oil pump to obtain a liquid white oily composition containing 1.0% by weight of insulin.
The water content in the oily composition was 0.1% by weight. The water content in the solid phase dispersed in the oil phase was 0.6% by weight, the insulin content was 6.2% by weight, and the amount of gelatin relative to 100 parts by weight of insulin was 1000 parts by weight. The gelatin content in the solid phase was 62.1% by weight, and the glycerin content was 31.1% by weight. The average particle size of the solid phase was 1.8 μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 1 shows the evaluation results.
【0044】比較参考例1 霊芝エキス末70.0g、ゼラチンA−U、120.0
g、ソルビットL−70、70.0g、水360.0g
を混合して60℃に加温したものを水相とし、大豆油3
50.0g、SYグリスターTS−310、30.0g
を混合して60℃で溶解させたものを油相とした。この
油相に前記水相をゆっくり添加し、攪拌棒で20分間攪
拌乳化することによりW/O乳化物を得た。次いで、得
られた乳化物をオイルポンプを用いて減圧脱水すること
により、霊芝エキス11.3重量%含有する液状茶色の
油性組成物を得た。油性組成物中の水分含有量は0.2
重量%であった。油相中に分散している固体相中の水分
含有量は0.5重量%、霊芝エキスの含有量は29.1
重量%で、霊芝エキス100重量部に対するゼラチンの
量は171.4重量部であった。また、固体相中のゼラ
チン含有量は50.0重量%、D−ソルビット含有量は
20.4重量%であった。固体相の平均粒子径は7.2
μmであった。得られた油性組成物の保存安定性につい
て、参考例1と同様の評価を行った。評価結果を表2に
示す。Comparative Reference Example 1 Reishi extract powder 70.0 g, gelatin AU, 120.0 g
g, sorbit L-70, 70.0 g, water 360.0 g
And heated to 60 ° C. to form an aqueous phase, soybean oil 3
50.0 g, SY Glister TS-310, 30.0 g
Were dissolved at 60 ° C. to obtain an oil phase. The water phase was slowly added to the oil phase, and the mixture was emulsified with a stirring bar for 20 minutes to obtain a W / O emulsion. Next, the obtained emulsion was dehydrated under reduced pressure using an oil pump to obtain a liquid brown oily composition containing 11.3% by weight of Reishi extract. The water content in the oily composition is 0.2
% By weight. The water content in the solid phase dispersed in the oil phase is 0.5% by weight, and the content of Reishi extract is 29.1.
In terms of% by weight, the amount of gelatin per 100 parts by weight of Reishi extract was 171.4 parts by weight. The gelatin content in the solid phase was 50.0% by weight, and the D-sorbitol content was 20.4% by weight. The average particle size of the solid phase is 7.2
μm. The storage stability of the obtained oily composition was evaluated in the same manner as in Reference Example 1. Table 2 shows the evaluation results.
【0045】比較参考例2 霊芝エキス末70.0g、ゼラチンA−U、120.0
g、ソルビットL−70、70.0g、水360.0g
を混合して60℃に加温したものを水相とし、大豆油3
50.0g、SYグリスターTS−310、30.0g
を混合して60℃で溶解させたものを油相とした。この
油相に前記水相をゆっくり添加しながらホモミキサーを
用いて6000rpmで20分間、60℃で混合乳化する
ことにより霊芝エキス7.0重量%含有する液状茶色の
W/O乳化物を得た。乳化物中の水分含有量は38.1
重量%であった。水相中の水分含有量は61.5重量
%、霊芝エキスの含有量は11.3重量%で、霊芝エキ
ス100重量部に対するゼラチンの量は171.4重量
部であった。また、水相中のゼラチン含有量は19.3
重量%、D−ソルビット含有量は7.9重量%であっ
た、乳化粒子の平均粒子径は1.8μmであった。得ら
れた乳化組成物の保存安定性について、参考例1と同様
の評価を行った。評価結果を表2に示す。Comparative Reference Example 2 Reishi extract powder 70.0 g, gelatin AU, 120.0 g
g, sorbit L-70, 70.0 g, water 360.0 g
And heated to 60 ° C. to form an aqueous phase, soybean oil 3
50.0 g, SY Glister TS-310, 30.0 g
Were dissolved at 60 ° C. to obtain an oil phase. A liquid brown W / O emulsion containing 7.0% by weight of Reishi extract was obtained by mixing and emulsifying at 60 ° C. for 20 minutes at 6000 rpm using a homomixer while slowly adding the aqueous phase to the oil phase. Was. The water content in the emulsion is 38.1
% By weight. The water content in the aqueous phase was 61.5% by weight, the content of Reishi extract was 11.3% by weight, and the amount of gelatin relative to 100 parts by weight of Reishi extract was 171.4 parts by weight. The gelatin content in the aqueous phase was 19.3.
% By weight, the D-sorbite content was 7.9% by weight, and the average particle size of the emulsified particles was 1.8 μm. The same evaluation as in Reference Example 1 was performed for the storage stability of the obtained emulsion composition. Table 2 shows the evaluation results.
【0046】比較参考例3 アスコルビン酸70.0g、ゼラチンA−U、70.0
g、セルエース#25、30.0g、ベイシスLG−1
0K、1.0g、水429.0gを混合溶解したものを
水相(60℃)とし、ODO、300.0g、トコフェ
ロール100、50.0g、ポエムPR−300、5
0.0gを混合して60℃で溶解させたものを油相とし
た。この油相に前記水相をゆっくり添加しながらホモミ
キサーを用いて6000rpmで20分間、60℃で混合
乳化することによりW/O乳化物を得た。次いで、得ら
れた乳化物をオイルポンプを用いて参考例6よりも短い
時間乾燥することにより、アスコルビン酸を10.7重
量%含有し、参考例6よりも水分含有量が多い液状白色
のW/O乳化物を得た。乳化物中の水分含有量は12.
7重量%であった。水相中の水分含有量は32.6重量
%、アスコルビン酸の含有量は27.6重量%で、アス
コルビン酸100重量部に対するゼラチン及びコーンフ
ァイバーの量は142.9重量部であった。また、水相
中のゼラチン及びコーンファイバー含有量は39.4重
量%であった。乳化粒子の平均粒子径は1.4μmであ
った。得られた乳化組成物の保存安定性について、参考
例1と同様の評価を行った。評価結果を表2に示す。Comparative Reference Example 3 70.0 g of ascorbic acid, gelatin AU, 70.0 g
g, Cell Ace # 25, 30.0 g, Basis LG-1
A solution obtained by mixing and dissolving 1.0 g of 0K and 429.0 g of water was used as an aqueous phase (60 ° C.), and ODO, 300.0 g, tocopherol 100, 50.0 g, Poem PR-300,
A mixture obtained by mixing 0.0 g and dissolving at 60 ° C. was used as an oil phase. A W / O emulsion was obtained by mixing and emulsifying at 60 ° C. for 20 minutes at 6000 rpm using a homomixer while slowly adding the aqueous phase to the oil phase. Next, the obtained emulsion was dried using an oil pump for a shorter time than in Reference Example 6, so that liquid white W containing 10.7% by weight of ascorbic acid and having a higher moisture content than Reference Example 6. / O emulsion was obtained. The water content in the emulsion is 12.
7% by weight. The water content in the aqueous phase was 32.6% by weight, the content of ascorbic acid was 27.6% by weight, and the amount of gelatin and corn fiber relative to 100 parts by weight of ascorbic acid was 142.9 parts by weight. The content of gelatin and corn fiber in the aqueous phase was 39.4% by weight. The average particle size of the emulsified particles was 1.4 μm. The same evaluation as in Reference Example 1 was performed for the storage stability of the obtained emulsion composition. Table 2 shows the evaluation results.
【0047】比較参考例4 霊芝エキス末70.0g、ゼラチンA−U、120.0
g、ソルビットL−70、70.0g、水360.0
g、デカグリセリンモノオレート(阪本薬品工業(株)
製、SYグリスターMO−750、HLB:13)3
0.0gを混合して60℃に加温したものを水相とし、
大豆油350.0gを60℃で溶解させたものを油相と
した。この油相に前記水相をゆっくり添加しながらホモ
ミキサーを用いて6000rpmで20分間、60℃で混
合乳化を行ったが、W/O乳化物が転相してO/W乳化
物となってしまい、油性組成物は得られなかった。Comparative Reference Example 4 Reishi extract powder 70.0 g, gelatin AU, 120.0 g
g, sorbit L-70, 70.0 g, water 360.0
g, decaglycerin monooleate (Sakamoto Pharmaceutical Co., Ltd.)
SY Glister MO-750, HLB: 13) 3
The aqueous phase was obtained by mixing 0.0 g and heating to 60 ° C.
What melt | dissolved 350.0 g of soybean oil at 60 degreeC was used as the oil phase. While the aqueous phase was slowly added to the oil phase, mixed emulsification was performed at 6000 rpm for 20 minutes at 60 ° C. using a homomixer, but the W / O emulsion was phase-inverted to become an O / W emulsion. As a result, no oily composition was obtained.
【0048】[0048]
【表1】 [Table 1]
【0049】[0049]
【表2】 [Table 2]
【0050】実施例1 参考例1で得た油性組成物30g、グリセリン脂肪酸モ
ノエステル(理研ビタミン(株)製、エマルジーMU)
0.5gを混合し、60℃に加温した。化工澱粉(松谷
化学工業(株)製、エマルスター#30A)20g、澱
粉加水分解物(松谷化学工業(株)製、パインデックス
#3)149.5g、水400gを混合して60℃に加
温したものを水相とした。この水相に前記油性組成物を
ゆっくり添加しながらホモミキサーを用いて4000rp
mで20分間乳化することにより、白色の乳化液を得
た。この乳化液をスプレードライ乾燥することにより、
霊芝エキスを含有する流動性の良い粉末組成物を得た。
また、得られた粉末組成物1gを水99gに添加するこ
とにより、白色の乳化液を得た。この乳化液を顕微鏡で
観測すると、油粒子中には5μm以下の固体相微粒子が
存在していた。Example 1 30 g of the oily composition obtained in Reference Example 1, glycerin fatty acid monoester (Emulgy MU, manufactured by Riken Vitamin Co., Ltd.)
0.5 g were mixed and heated to 60 ° C. 20 g of chemically modified starch (Emulstar # 30A, manufactured by Matsutani Chemical Industry Co., Ltd.), 149.5 g of starch hydrolyzate (Paindex # 3, manufactured by Matsutani Chemical Industry Co., Ltd.) and 400 g of water were mixed and heated to 60 ° C. This was used as the aqueous phase. 4000 rp using a homomixer while slowly adding the oily composition to the aqueous phase.
By emulsifying at 20 m for 20 minutes, a white emulsion was obtained. By spray-drying this emulsion,
A powder composition having good fluidity containing the Reishi extract was obtained.
In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. When this emulsion was observed with a microscope, solid phase fine particles of 5 μm or less were present in the oil particles.
【0051】実施例2 参考例2で得た油性組成物30g、エマルジーMU0.
5gを混合し、60℃に加温した。エマルスター#30
A、20g、パインデックス#3、149.5g、水4
00gを混合して60℃に加温したものを水相とした。
以下実施例1と同様に操作を行うことにより、霊芝エキ
スを含有する流動性の良い粉末組成物を得た。また、得
られた粉末組成物1gを水99gに添加することによ
り、白色の乳化液を得た。この乳化液を顕微鏡で観測す
ると、油粒子中には5μm以下の固体相微粒子が存在し
ていた。Example 2 30 g of the oily composition obtained in Reference Example 2 and Emulgy MU0.
5 g were mixed and heated to 60 ° C. Emulstar # 30
A, 20 g, par index # 3, 149.5 g, water 4
The resulting mixture was heated to 60 ° C., and the resulting mixture was used as an aqueous phase.
Thereafter, the same operation as in Example 1 was performed to obtain a powder composition having good fluidity containing the Reishi extract. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. When this emulsion was observed with a microscope, solid phase fine particles of 5 μm or less were present in the oil particles.
【0052】実施例3 参考例3で得た油性組成物30g、エマルジーMU0.
5gを混合し、60℃に加温した。エマルスター#30
A、20g、パインデックス#3、149.5g、水4
00gを混合して60℃に加温したものを水相とした。
以下実施例1と同様に操作を行うことにより、霊芝エキ
スを含有する流動性の良い粉末組成物を得た。また、得
られた粉末組成物1gを水99gに添加することによ
り、白色の乳化液を得た。この乳化液を顕微鏡で観測す
ると、油粒子中には5μm以下の固体相微粒子が存在し
ていた。Example 3 30 g of the oily composition obtained in Reference Example 3, Emulgy MU0.
5 g were mixed and heated to 60 ° C. Emulstar # 30
A, 20 g, par index # 3, 149.5 g, water 4
The resulting mixture was heated to 60 ° C., and the resulting mixture was used as an aqueous phase.
Thereafter, the same operation as in Example 1 was performed to obtain a powder composition having good fluidity containing the Reishi extract. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. When this emulsion was observed with a microscope, solid phase fine particles of 5 μm or less were present in the oil particles.
【0053】実施例4 参考例4で得た油性組成物30g、エマルジーMU0.
5gを混合し、60℃に加温した。エマルスター#30
A、20g、パインデックス#3、149.5g、水4
00gを混合して60℃に加温したものを水相とした。
以下実施例1と同様に操作を行うことにより、グルタミ
ン酸ナトリウムを含有する流動性の良い粉末組成物を得
た。また、得られた粉末組成物1gを水99gに添加す
ることにより、白色の乳化液を得た。この乳化液を顕微
鏡で観測すると、油粒子中には5μm以下の固体相微粒
子が存在していた。Example 4 30 g of the oily composition obtained in Reference Example 4, Emulgy MU0.
5 g were mixed and heated to 60 ° C. Emulstar # 30
A, 20 g, par index # 3, 149.5 g, water 4
The resulting mixture was heated to 60 ° C., and the resulting mixture was used as an aqueous phase.
Thereafter, the same operation as in Example 1 was performed to obtain a powder composition having good fluidity containing sodium glutamate. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. When this emulsion was observed with a microscope, solid phase fine particles of 5 μm or less were present in the oil particles.
【0054】実施例5 参考例5で得た油性組成物20gを油相(60℃)とし
た。ヘキサグリセリンモノオレート(阪本薬品工業
(株)製、SYグリスターMO−500)1g、プルラ
ン((株)林原製、プルラン)5g、パインデックス#
3、174g、水400gを混合して60℃に加温した
ものを水相とした。この水相に前記油相をゆっくり添加
しながらホモミキサーを用いて6000rpmで20分間
乳化し、さらに高圧ホモジナイザーを用いて50kg/cm
2の圧力で乳化処理することにより、黄色の乳化液を得
た。この乳化液をスプレードライ乾燥することにより、
茶抽出物を含有する流動性の良い粉末組成物を得た。ま
た、得られた粉末組成物1gを水99gに添加すること
により、白色の乳化液を得た。この乳化液を顕微鏡で観
測すると、油粒子中には5μm以下の固体相微粒子が存
在していた。Example 5 20 g of the oily composition obtained in Reference Example 5 was used as an oil phase (60 ° C.). Hexaglycerol monooleate (Sakamoto Yakuhin Kogyo Co., Ltd., SY Glister MO-500) 1 g, pullulan (Hayashibara Co., Ltd., pullulan) 5 g, Paindex #
3, 174 g and 400 g of water were mixed and heated to 60 ° C. to obtain an aqueous phase. While slowly adding the oil phase to the aqueous phase, the mixture was emulsified at 6000 rpm for 20 minutes using a homomixer, and then 50 kg / cm using a high-pressure homogenizer.
By emulsifying at a pressure of 2 , a yellow emulsion was obtained. By spray-drying this emulsion,
A powder composition containing tea extract and having good fluidity was obtained. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. When this emulsion was observed with a microscope, solid phase fine particles of 5 μm or less were present in the oil particles.
【0055】実施例6 澱粉加水分解物(松谷化学工業(株)製、パインデック
ス#1)160gをホバートミキサーに投入し、粉末を
回転流動させているところへ、参考例6で得た油性組成
物40g(50℃)をゆっくり滴下後、20分間攪拌す
ることにより、アスコルビン酸を含有する流動性の良い
粉末組成物を得た。また、得られた粉末組成物1gを水
99gに添加することにより、白色の乳化液を得た。こ
の乳化液を顕微鏡で観測すると、油粒子中には5μm以
下の固体相微粒子が存在していた。Example 6 160 g of a starch hydrolyzate (Paindex # 1 manufactured by Matsutani Chemical Industry Co., Ltd.) was charged into a Hobart mixer, and the oily composition obtained in Reference Example 6 was added while the powder was being rotated and fluidized. After slowly dropping 40 g (50 ° C.) of the product, the mixture was stirred for 20 minutes to obtain a powder composition containing ascorbic acid and having good fluidity. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. When this emulsion was observed with a microscope, solid phase fine particles of 5 μm or less were present in the oil particles.
【0056】実施例7 参考例7で得た油性組成物80gを60℃に加温した。
大豆蛋白加水分解物(日清製油(株)製、ソルピー20
00)4g、パインデックス#3、116g、水400
gを混合して60℃に加温したものを水相とした。以下
実施例1と同様に操作することにより、白色の乳化液を
得た。この乳化液を凍結乾燥することにより、塩化カル
シウムを含有する流動性の良い粉末組成物を得た。ま
た、得られた粉末組成物1gを水99gに添加すること
により、白色の乳化液を得た。この乳化液を顕微鏡で観
測すると、油粒子中には5μm以下の固体相微粒子が存
在していた。Example 7 80 g of the oily composition obtained in Reference Example 7 was heated to 60 ° C.
Soy protein hydrolyzate (Solpy 20 manufactured by Nisshin Oil Co., Ltd.)
00) 4 g, par index # 3, 116 g, water 400
g and heated to 60 ° C. to form an aqueous phase. Thereafter, the same operation as in Example 1 was performed to obtain a white emulsion. This emulsion was freeze-dried to obtain a powder composition having good flowability containing calcium chloride. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. When this emulsion was observed with a microscope, solid phase fine particles of 5 μm or less were present in the oil particles.
【0057】実施例8 参考例8で得た油性組成物40gを60℃に加温した。
アラビアガム(三栄薬品貿易(株)製、アラビックコー
ルSS)60g、パインデックス#3、100g、水4
00gを混合して60℃に加温したものを水相とした。
この水相に前記油性組成物をゆっくり添加しながらホモ
ミキサーを用いて6000rpmで20分間乳化処理する
ことにより、茶色の乳化液を得た。この乳化液を凍結乾
燥することにより、高麗人参エキスを含有する流動性の
良い粉末組成物を得た。また、得られた粉末組成物1g
を水99gに添加することにより、白色の乳化液を得
た。この乳化液を顕微鏡で観測すると、油粒子中には5
μm以下の固体相微粒子が存在していた。Example 8 40 g of the oily composition obtained in Reference Example 8 was heated to 60 ° C.
Gum arabic (Arabic Cole SS, manufactured by Sanei Pharmaceutical Trading Co., Ltd.) 60 g, Paindex # 3, 100 g, water 4
The resulting mixture was heated to 60 ° C., and the resulting mixture was used as an aqueous phase.
The oily composition was slowly added to the aqueous phase and emulsified at 6000 rpm for 20 minutes using a homomixer to obtain a brown emulsion. The emulsion was freeze-dried to obtain a powder composition containing ginseng extract with good fluidity. In addition, 1 g of the obtained powder composition
Was added to 99 g of water to obtain a white emulsion. When this emulsion was observed with a microscope, it was found that 5
Solid phase fine particles of μm or less were present.
【0058】実施例9 パインデックス160gをホバートミキサーに投入し、
粉末を回転流動させているところへ、参考例9で得た油
性組成物40g(50℃)をゆっくり滴下後、20分間
攪拌することにより、ビタミンB1を含有する流動性の
良い粉末組成物を得た。また、得られた粉末組成物1g
を水99gに添加することにより、白色の乳化液を得
た。この乳化液を顕微鏡で観測すると、油粒子中には5
μm以下の固体相微粒子が存在していた。Example 9 160 g of parindex was put into a Hobart mixer,
The powder to where that rotates flow, after slowly added dropwise to the oily composition obtained in Reference Example 9 40g (50 ℃), by stirring for 20 minutes, the fluidity good powder composition containing vitamin B 1 Obtained. In addition, 1 g of the obtained powder composition
Was added to 99 g of water to obtain a white emulsion. When this emulsion was observed with a microscope, it was found that 5
Solid phase fine particles of μm or less were present.
【0059】実施例10 パインデックス#1、160gをホバートミキサーに投
入し、粉末を回転流動させているところへ、参考例10
で得た油性組成物40g(50℃)をゆっくり滴下後、
20分間攪拌することにより、ビタミンB1を含有する
流動性の良い粉末組成物を得た。また、得られた粉末組
成物1gを水99gに添加することにより、白色の乳化
液を得た。この乳化液を顕微鏡で観測すると、油粒子中
には5μm以下の固体相微粒子が存在していた。Example 10 160 g of Paindex # 1 was charged into a Hobart mixer, and the powder was rotated and fluidized.
After slowly dropping 40 g (50 ° C.) of the oily composition obtained in the above,
By stirring for 20 minutes to obtain a flowable good powder composition containing vitamin B 1. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. When this emulsion was observed with a microscope, solid phase fine particles of 5 μm or less were present in the oil particles.
【0060】実施例11 パインデックス#1、190gをホバートミキサーに投
入し、粉末を回転流動させているところへ、参考例11
で得た油性組成物10g(30℃)をゆっくり滴下後、
20分間攪拌することにより、インスリンを含有する流
動性の良い粉末組成物を得た。また、得られた粉末組成
物1gを水99gに添加することにより、白色の乳化液
を得た。この乳化液を顕微鏡で観測すると、油粒子中に
は5μm以下の固体相微粒子が存在していた。Example 11 190 g of parindex # 1 was charged into a Hobart mixer, and the powder was rotated and fluidized.
After slowly dropping 10 g (30 ° C.) of the oily composition obtained in the above,
By stirring for 20 minutes, a powder composition having good fluidity containing insulin was obtained. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. When this emulsion was observed with a microscope, solid phase fine particles of 5 μm or less were present in the oil particles.
【0061】比較例1 比較参考例1で得たW/O型乳化物30g、エマルジー
MU0.5gを混合し60℃に加温した。エマルスター
#30A、20g、パインデックス#3、149.5
g、水400gを混合して60℃に加温したものを水相
とした。以下実施例1と同様に操作することにより、霊
芝エキスを含有する流動性の良い粉末組成物を得た。ま
た、得られた粉末組成物1gを水99gに添加すること
により、白色の乳化液を得た。この乳化液を顕微鏡で観
測したが、油粒子中に粒子は存在していなかった。Comparative Example 1 30 g of the W / O emulsion obtained in Comparative Reference Example 1 and 0.5 g of Emulgy MU were mixed and heated to 60 ° C. Emulstar # 30A, 20g, Paindex # 3, 149.5
g and 400 g of water and heated to 60 ° C. to obtain an aqueous phase. Thereafter, the same operation as in Example 1 was carried out to obtain a powder composition having good fluidity containing the Reishi extract. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. The emulsion was observed with a microscope, but no particles were present in the oil particles.
【0062】比較例2 比較参考例2で得た油性組成物30g、エマルジーMU
0.5gを混合し60℃に加温した。エマルスター#3
0A、20g、パインデックス#3、149.5g、水
400gを混合して60℃に加温したものを水相とし
た。以下実施例1と同様に操作することにより、霊芝エ
キスを含有する粉末組成物を得た。得られた粉末組成物
は、小さい塊を多く有し、湿り気のある粉体性状の悪い
ものであった。また、得られた粉末組成物1gを水99
gに添加することにより、白色の乳化液を得た。この乳
化液を顕微鏡で観測したが、油粒子中に粒子は存在して
いなかった。Comparative Example 2 30 g of the oily composition obtained in Comparative Reference Example 2, Emulgy MU
0.5 g was mixed and heated to 60 ° C. Emulstar # 3
A mixture of 0A, 20 g, Paindex # 3, 149.5 g, and 400 g of water and heated to 60 ° C. was used as an aqueous phase. Thereafter, the same operation as in Example 1 was performed to obtain a powder composition containing the reishi extract. The resulting powder composition had many small lumps and was moist and had poor powder properties. Also, 1 g of the obtained powder composition was added to water 99
By adding to g, a white emulsion was obtained. The emulsion was observed with a microscope, but no particles were present in the oil particles.
【0063】比較例3 パインデックス#1、160gをホバートミキサーに投
入し、粉末を回転流動させているところへ、比較参考例
3で得た油性組成物40g(50℃)をゆっくり滴下
後、20分間攪拌することにより、アスコルビン酸を含
有する粉末組成物を得た。得られた粉末組成物は、湿り
気のある流動性の低い粉末であった。また、得られた粉
末組成物1gを水99gに添加することにより、白色の
乳化液を得た。この乳化液を顕微鏡で観測したが、油粒
子中に粒子は存在していなかった。Comparative Example 3 40 g of the oily composition obtained in Comparative Reference Example 3 (50 ° C.) was slowly dropped into 160 g of Paindex # 1 in a Hobart mixer while the powder was being rotated and fluidized. By stirring for minutes, a powder composition containing ascorbic acid was obtained. The resulting powder composition was a moist, low-flow powder. In addition, a white emulsion was obtained by adding 1 g of the obtained powder composition to 99 g of water. The emulsion was observed with a microscope, but no particles were present in the oil particles.
【0064】(特定の油性組成物を含有する粉末組成物
の味覚試験)実施例1〜10、比較例1〜3で調製した
各種水性有効物質を含有する粉末組成物の味覚試験を健
常人20名に対して実施した。また、粉末組成物30g
を100gの水に混合した直後及び3時間プロペラ攪拌
後の溶液の味覚試験も実施した。それらの結果を表3に
示す。(Taste Test of Powder Composition Containing a Specific Oily Composition) The taste test of the powder compositions containing various aqueous active substances prepared in Examples 1 to 10 and Comparative Examples 1 to 3 was carried out on a healthy person 20. Conducted on the first name. 30 g of the powder composition
Was also mixed immediately after mixing with 100 g of water and after stirring the propeller for 3 hours. Table 3 shows the results.
【0065】[0065]
【表3】 [Table 3]
【0066】[水性有効物質の保存安定性試験]実施例
6、比較例3の粉末組成物を、40℃の恒温槽で1ヶ月
間保存したときのアスコルビン酸残存率(%)を調べ
た。アスコルビン酸残存率の測定は、高速液体クロマト
グラフィー法を用いて行った。その結果を表4示す。[Storage Stability Test of Aqueous Active Substance] The residual ratio (%) of ascorbic acid when the powder compositions of Example 6 and Comparative Example 3 were stored in a thermostat at 40 ° C. for one month was examined. The measurement of the residual ratio of ascorbic acid was performed using a high performance liquid chromatography method. Table 4 shows the results.
【0067】[0067]
【表4】 [Table 4]
【0068】[カルシウムの吸収試験]塩化カルシウム
粉末又は実施例7の粉末組成物を、カルシウム含量が
0.2%となるよう飼料に混合し、それぞれの飼料を体
重約200gのWistar系雄性ラット10匹に10日間
与え、カルシウムの出納実験を行うことにより、カルシ
ウムの吸収率を調べた。カルシウム吸収試験結果を表5
に示す。[Calcium Absorption Test] Calcium chloride powder or the powder composition of Example 7 was mixed with feed so that the calcium content was 0.2%, and each feed was mixed with a Wistar male rat 10 having a body weight of about 200 g. The animals were fed for 10 days, and a calcium balance experiment was performed to determine the calcium absorption rate. Table 5 shows the results of the calcium absorption test.
Shown in
【0069】[0069]
【表5】 [Table 5]
【0070】[インスリンの吸収性試験]リン酸生理食
塩水で調製したインスリン溶液又は実施例11の粉末組
成物を、体重約200gのWistar系雄性ラット10匹ラ
ットにインスリンとして50U/kgとなる量を5日間経
口投与し、投与最終日に採血を行い血中の血糖値を調べ
た。その結果、インスリン投与前と比較して、インスリ
ン溶液を経口投与したラットの血糖値は変化はほとんど
無かったが、実施例11の粉末組成物を経口投与したラ
ットは血糖値の低下が見られた。[Insulin Absorbency Test] An insulin solution prepared with a physiological saline phosphate solution or the powder composition of Example 11 was used to give 50 U / kg of insulin to 10 Wistar male rats weighing about 200 g. Was orally administered for 5 days, blood was collected on the last day of the administration, and the blood glucose level in the blood was examined. As a result, the blood glucose level of the rats to which the insulin solution was orally administered was almost unchanged as compared to before the insulin administration, but the blood glucose level of the rats to which the powder composition of Example 11 was orally administered was decreased. .
【0071】[0071]
【発明の効果】以上、詳述した通り、本発明の粉末組成
物は、特定の油性組成物を、粉末基材に吸着・内包させ
たものである。特定の油性組成物とは、水性有効物質、
水溶性フィルム形成剤を含有し、好ましくは多価アルコ
ールを含有してなる固体相と、油性成分及びHLBが1
0以下の乳化剤を含有してなる油相とからなる油性組成
物であって、上記固体相が、平均粒子径5μm以下の微
粒子状態で油相中に分散しており、且つ上記固体相中の
水分含有量が30重量%以下のものである。そのため、
上記特定の油性組成物を含有する粉末組成物は、水性有
効物質の味が低減又はマスキングされており、且つ水性
有効物質が劣化しにくい。また、水性有効物質の体内吸
収率を向上させることができる。また、本発明の粉末組
成物は、水性有効物質の味の低減や徐放効果、マスキン
グ効果、体内吸収率向上効果を有するため、食品、飼
料、医薬品、農薬において利用することができる。ま
た、水性有効物質が劣化しにくいため、機械その他各種
工業分野において利用することができる。As described in detail above, the powder composition of the present invention is obtained by adsorbing and enclosing a specific oily composition in a powder base material. Specific oily compositions are aqueous active substances,
A solid phase containing a water-soluble film-forming agent, preferably containing a polyhydric alcohol;
An oily composition comprising an oil phase containing 0 or less emulsifier, wherein the solid phase is dispersed in the oil phase in a fine particle state having an average particle diameter of 5 μm or less, and The water content is 30% by weight or less. for that reason,
In the powder composition containing the specific oily composition, the taste of the aqueous active substance is reduced or masked, and the aqueous active substance is hardly deteriorated. In addition, the rate of absorption of the aqueous active substance in the body can be improved. Further, the powder composition of the present invention has a taste-reducing effect, a sustained-release effect, a masking effect, and an effect of improving the absorption rate in the body of the aqueous active substance, and thus can be used in foods, feeds, pharmaceuticals, and agricultural chemicals. Further, since the water-based active substance hardly deteriorates, it can be used in machines and other various industrial fields.
───────────────────────────────────────────────────── フロントページの続き Fターム(参考) 2B150 AB20 AE02 AE31 DJ01 DJ08 DJ10 DJ11 DJ13 DJ26 4C076 AA06 AA16 AA29 AA36 BB01 BB31 CC01 CC03 CC04 CC06 CC09 CC11 CC16 CC21 CC22 CC27 CC32 CC40 DD34 DD38 DD45 DD46 DD63 DD64 DD67 DD68 DD70 EE06 EE09 EE16 EE23 EE24 EE27 EE30 EE31 EE32 EE33 EE38 EE39 EE41 EE42 EE48 EE53 EE54 EE55 EE58 FF31 FF34 FF52 FF65 4G005 AA01 AB15 AB25 AB27 BA12 BB06 BB12 BB17 DA09X DA14X DB06Z DB11Z DB12X DB13Z DB16Z DB22X DB23X DC32W EA01 EA02 EA03 ──────────────────────────────────────────────────続 き Continued on the front page F term (reference) 2B150 AB20 AE02 AE31 DJ01 DJ08 DJ10 DJ11 DJ13 DJ26 4C076 AA06 AA16 AA29 AA36 BB01 BB31 CC01 CC03 CC04 CC06 CC09 CC11 CC16 CC21 CC22 CC27 CC32 CC40 DD34 DD38 DD45 DD46 DD63 DD64 DD67 DD68 EE06 EE09 EE16 EE23 EE24 EE27 EE30 EE31 EE32 EE33 EE38 EE39 EE41 EE42 EE48 EE53 EE54 EE55 EE58 FF31 FF34 FF52 FF65 4G005 AA01 AB15 AB25 AB27 BA12 BB06 BB12 BB17 DB09XDA
Claims (8)
物質、及び水溶性フィルム形成剤を含有してなる固体相
と、油性成分及びHLBが10以下の乳化剤を含有して
なる油相とからなる油性組成物であって、上記固体相
が、平均粒子径5μm以下の微粒子状態で油相中に分散
しており、上記固体相中の水分含有量又はアルコール水
溶液含有量が30重量%以下である上記油性組成物と、
粉末化基材とからなることを特徴とする粉末組成物。1. A solid phase containing a water-soluble active substance and / or a water-dispersible active substance and a water-soluble film forming agent, and an oil phase containing an oil component and an emulsifier having an HLB of 10 or less. Wherein the solid phase is dispersed in the oil phase in the form of fine particles having an average particle diameter of 5 μm or less, and the water content or the aqueous alcohol content of the solid phase is 30% by weight or less. The oily composition is
A powder composition comprising a powdered base material.
にさらに加えて乳化剤からなることを特徴とする粉末組
成物。2. A powder composition comprising the oily composition according to claim 1 and an emulsifier in addition to the powdered base material.
が、固体相の全重量に対して1〜95重量%含有するも
のである請求項1又は2記載の粉末組成物。3. The powder composition according to claim 1, wherein the water-soluble film-forming agent according to claim 1 is contained in an amount of 1 to 95% by weight based on the total weight of the solid phase.
が、ゼラチン、にかわ、アラビアガム、澱粉微生物培養
物、ヘミセルロース、水溶性被膜形成合成高分子から選
ばれる1又は2以上のものである請求項1〜3の何れか
1項記載の粉末組成物。4. The water-soluble film-forming agent according to claim 3, which is one or more selected from gelatin, glue, gum arabic, starch microbial culture, hemicellulose, and a water-soluble film-forming synthetic polymer. Item 4. The powder composition according to any one of Items 1 to 3.
相の全重量に対して、分子内に2つ以上の水酸基を有す
る多価アルコールを1〜90重量%含有するものである
請求項1〜4の何れか1項記載の粉末組成物。5. The oily composition according to claim 1, which contains 1 to 90% by weight of a polyhydric alcohol having two or more hydroxyl groups in a molecule with respect to the total weight of the solid phase. Item 5. The powder composition according to any one of Items 1 to 4.
に油溶性有効物質を含有するものである請求項1〜5の
何れか1項記載の粉末組成物。6. The powder composition according to claim 1, wherein the oily composition according to claim 1 or 2 contains an oil-soluble active substance in an oil phase.
相を5〜75重量%含有し、油相を95〜25重量%含
有するものである請求項1〜6の何れか1項記載の粉末
組成物。7. The oily composition according to claim 1, which contains 5 to 75% by weight of a solid phase and 95 to 25% by weight of an oil phase. A powder composition as described.
質、水溶性フィルム形成剤、並びに水又はアルコール水
溶液を含有した水相と、油性成分及び乳化剤を含有する
油相とを乳化したW/O型乳化物を乾燥処理することに
より得られる油性組成物を用いた請求項1〜7の何れか
1項記載の粉末組成物。8. W / Emulsified water phase containing water-soluble active substance and / or water-dispersible substance, water-soluble film-forming agent and water or alcohol aqueous solution, and oil phase containing oil component and emulsifier. The powder composition according to any one of claims 1 to 7, wherein an oily composition obtained by drying the O-type emulsion is used.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10195513A JP2000026283A (en) | 1998-07-10 | 1998-07-10 | Powder composition containing oily composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10195513A JP2000026283A (en) | 1998-07-10 | 1998-07-10 | Powder composition containing oily composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000026283A true JP2000026283A (en) | 2000-01-25 |
Family
ID=16342338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10195513A Pending JP2000026283A (en) | 1998-07-10 | 1998-07-10 | Powder composition containing oily composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000026283A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002011340A (en) * | 2000-06-28 | 2002-01-15 | Toppan Forms Co Ltd | Manufacturing method of dual capsule |
| FR2851918A1 (en) * | 2003-03-06 | 2004-09-10 | Galenix Innovations | Powder for giving improved biodispersibility and solubility, comprises that it is impregnated with a mixture of hydrophobic and hydrophilic liquids having an active material as a solution in one phase and a suspension in the other |
| JP2007503293A (en) * | 2003-08-22 | 2007-02-22 | ダニスコ エイ/エス | Micro capsule |
| WO2007052738A1 (en) * | 2005-11-04 | 2007-05-10 | Otsuka Pharmaceutical Co., Ltd. | Medicinal composition showing improved drug absorbability |
| WO2008004509A1 (en) * | 2006-07-03 | 2008-01-10 | The Nisshin Oillio Group, Ltd. | Squalene-containing oil composition and squalene-containing water-in-oil emulsion |
| JP2009526748A (en) * | 2006-02-17 | 2009-07-23 | ベリトロン・リミテッド | Calcium absorption promoter |
| JP2009178699A (en) * | 2008-02-01 | 2009-08-13 | Kanagawa Acad Of Sci & Technol | Method for producing aggregated particles |
| JP2011505156A (en) * | 2007-12-05 | 2011-02-24 | ディーエスエム アイピー アセッツ ビー.ブイ. | Finely pulverized preparation of fat-soluble active ingredients |
| JP2012521757A (en) * | 2009-03-26 | 2012-09-20 | アドバンスド バイオニュートリション コーポレーション | Microencapsulation of biologically active substance and method for producing the same |
| WO2014024971A1 (en) * | 2012-08-08 | 2014-02-13 | 積水化学工業株式会社 | Microcapsule-manufacturing process and microcapsules |
| WO2016002307A1 (en) * | 2014-06-30 | 2016-01-07 | ユニ・チャーム株式会社 | Method for producing granular pet food |
| WO2016002301A1 (en) * | 2014-06-30 | 2016-01-07 | ユニ・チャーム株式会社 | Method for manufacturing granular pet food |
| CN108308615A (en) * | 2018-01-12 | 2018-07-24 | 齐齐哈尔大学 | A kind of corn peptide is the preparation method of the lutein nanometer grain of carrier |
| WO2023054704A1 (en) * | 2021-09-30 | 2023-04-06 | 日産化学株式会社 | Method for producing complex dispersion in oil comprising water-soluble compound and lecithin |
| JP2023050678A (en) * | 2021-09-30 | 2023-04-11 | 阪本薬品工業株式会社 | Cellulose fiber dispersion composition |
-
1998
- 1998-07-10 JP JP10195513A patent/JP2000026283A/en active Pending
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002011340A (en) * | 2000-06-28 | 2002-01-15 | Toppan Forms Co Ltd | Manufacturing method of dual capsule |
| FR2851918A1 (en) * | 2003-03-06 | 2004-09-10 | Galenix Innovations | Powder for giving improved biodispersibility and solubility, comprises that it is impregnated with a mixture of hydrophobic and hydrophilic liquids having an active material as a solution in one phase and a suspension in the other |
| WO2004080381A3 (en) * | 2003-03-06 | 2005-07-28 | Sarl Galenix Innovations | Impregnated powder improving bioavailability and/or solubility and method of production |
| JP2007503293A (en) * | 2003-08-22 | 2007-02-22 | ダニスコ エイ/エス | Micro capsule |
| WO2007052738A1 (en) * | 2005-11-04 | 2007-05-10 | Otsuka Pharmaceutical Co., Ltd. | Medicinal composition showing improved drug absorbability |
| US8796309B2 (en) | 2005-11-04 | 2014-08-05 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical composition achieving excellent absorbency of pharmacologically active substance |
| JP5441337B2 (en) * | 2005-11-04 | 2014-03-12 | 大塚製薬株式会社 | Pharmaceutical composition with improved drug absorption |
| JP2009526748A (en) * | 2006-02-17 | 2009-07-23 | ベリトロン・リミテッド | Calcium absorption promoter |
| JP5150490B2 (en) * | 2006-07-03 | 2013-02-20 | 日清オイリオグループ株式会社 | Squalene-containing oily composition and squalene-containing oil-in-water emulsion |
| WO2008004509A1 (en) * | 2006-07-03 | 2008-01-10 | The Nisshin Oillio Group, Ltd. | Squalene-containing oil composition and squalene-containing water-in-oil emulsion |
| JP2011505156A (en) * | 2007-12-05 | 2011-02-24 | ディーエスエム アイピー アセッツ ビー.ブイ. | Finely pulverized preparation of fat-soluble active ingredients |
| JP2009178699A (en) * | 2008-02-01 | 2009-08-13 | Kanagawa Acad Of Sci & Technol | Method for producing aggregated particles |
| JP2012521757A (en) * | 2009-03-26 | 2012-09-20 | アドバンスド バイオニュートリション コーポレーション | Microencapsulation of biologically active substance and method for producing the same |
| US9445613B2 (en) | 2009-03-26 | 2016-09-20 | Advanced Bionutrition Corporation | Microencapsulation of bioactive substances and methods of making the same |
| JPWO2014024971A1 (en) * | 2012-08-08 | 2016-07-25 | 積水化学工業株式会社 | Microcapsule manufacturing method and microcapsule |
| CN104519990A (en) * | 2012-08-08 | 2015-04-15 | 积水化学工业株式会社 | Microcapsule-manufacturing process and microcapsules |
| WO2014024971A1 (en) * | 2012-08-08 | 2014-02-13 | 積水化学工業株式会社 | Microcapsule-manufacturing process and microcapsules |
| WO2016002307A1 (en) * | 2014-06-30 | 2016-01-07 | ユニ・チャーム株式会社 | Method for producing granular pet food |
| WO2016002301A1 (en) * | 2014-06-30 | 2016-01-07 | ユニ・チャーム株式会社 | Method for manufacturing granular pet food |
| JP2016010395A (en) * | 2014-06-30 | 2016-01-21 | ユニ・チャーム株式会社 | Granular pet food manufacturing method |
| CN108308615A (en) * | 2018-01-12 | 2018-07-24 | 齐齐哈尔大学 | A kind of corn peptide is the preparation method of the lutein nanometer grain of carrier |
| WO2023054704A1 (en) * | 2021-09-30 | 2023-04-06 | 日産化学株式会社 | Method for producing complex dispersion in oil comprising water-soluble compound and lecithin |
| JP2023050678A (en) * | 2021-09-30 | 2023-04-11 | 阪本薬品工業株式会社 | Cellulose fiber dispersion composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6190680B1 (en) | Oily composition and process for producing the same | |
| TWI391138B (en) | Cellooligosaccharide containing composition | |
| JP5343002B2 (en) | Bioactive substance-containing composition | |
| TWI351925B (en) | Composition comprising coenzyme q10 | |
| JP5377304B2 (en) | Coenzyme Q10-containing composition | |
| KR101840508B1 (en) | Beautiful-skin-promoting agent and use thereof | |
| JP2000026283A (en) | Powder composition containing oily composition | |
| WO2008053920A1 (en) | Physiologically active substance-containing granular composition and method of producing the same | |
| KR100724326B1 (en) | Coenzyme Q10-containing composition | |
| EP1931356A2 (en) | Butyric acid ester of carbohydrates and carbohydrate polyols | |
| ZA200301097B (en) | Water-dispersible encapsulated sterols. | |
| JP2000229118A (en) | Composition containing tea extract for deodorization and antioxidation | |
| EP3072397A1 (en) | Powdered oil or fat composition and process for producing same | |
| JPH11188256A (en) | Oily composition and its production | |
| JP2000157168A (en) | Oily composition and method for producing the same | |
| WO2005090534A1 (en) | Method for producing calcium component powder containing oil-soluble substance | |
| JP3502762B2 (en) | Oily composition and method for producing the same | |
| JP2000024487A (en) | Emulsified composition containing oily composition | |
| JP2004075541A (en) | Sterol-containing powder composition, compression molded product, production method and use | |
| KR102393620B1 (en) | manufacturing method of nanoemulsion composition containing quercein and nanoemulsion composition containing quercein prepared using the method | |
| JP2000026884A (en) | Powder composition containing oily composition | |
| JPH11113486A (en) | Oily composition and its production | |
| JP4913340B2 (en) | Capsule | |
| CN1450863A (en) | Cholesterol composition for reducing sterol compositions, preparation method of use | |
| JP4156234B2 (en) | Soft capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20040701 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090331 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090721 |